Source: http://www.google.com/patents/US20050148996?dq=KOI-18
Timestamp: 2017-03-26 15:30:48
Document Index: 19005686

Matched Legal Cases: ['Application No. 20030059673', 'art 850', 'in fine', 'art 855', 'art 855', 'art 855', 'arts 865', 'arts 460', 'art 865', 'art 865', 'arts 865', 'art 865', 'arts 870', 'arts 850', 'art 870', 'art 865']

Patent US20050148996 - Device for treatment of a barrier membrane - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a reservoir; wherein said power source is in electric communication with said first conductive electrode and said...http://www.google.com/patents/US20050148996?utm_source=gb-gplus-sharePatent US20050148996 - Device for treatment of a barrier membraneAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS20050148996 A1Publication typeApplicationApplication numberUS 11/019,557Publication dateJul 7, 2005Filing dateDec 22, 2004Priority dateJun 30, 2003Also published asCA2530593A1, EP1641524A1, US8475689, US8734421, US9050452, US20050010192, US20070060862, WO2005004981A2Publication number019557, 11019557, US 2005/0148996 A1, US 2005/148996 A1, US 20050148996 A1, US 20050148996A1, US 2005148996 A1, US 2005148996A1, US-A1-20050148996, US-A1-2005148996, US2005/0148996A1, US2005/148996A1, US20050148996 A1, US20050148996A1, US2005148996 A1, US2005148996A1InventorsYing Sun, Jue-Chen Liu, Jeffrey Wu, James HauschildOriginal AssigneeYing Sun, Jue-Chen Liu, Wu Jeffrey M., Hauschild James E.Export CitationBiBTeX, EndNote, RefManPatent Citations (99), Non-Patent Citations (3), Referenced by (114), Classifications (40), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetDevice for treatment of a barrier membrane
US 20050148996 A1Abstract
The present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a reservoir; wherein said power source is in electric communication with said first conductive electrode and said second conductive electrode, wherein said first conductive electrode and said second conductive electrode are arranged such that they are both capable of being in ionic communication with a carrier upon the inclusion of said carrier to said reservoir; and the use thereof. Images(16) Claims(26)
1. A device having a barrier membrane contacting surface, said device comprising: a power source; a first conductive electrode; a second conductive electrode; and a reservoir; wherein said power source is in electric communication with said first conductive electrode and said second conductive electrode, wherein said first conductive electrode and said second conductive electrode are arranged such that they are both capable of being in ionic communication with a carrier upon the inclusion of said carrier to said reservoir. 2. A device of claim 1, wherein said device comprises a housing and said reservoir is comprised within said housing. 3. A device of claim 1, wherein said reservoir comprises said carrier. 4. A device of claim 2, wherein said housing comprises an adhesive. 5. A device of claim 3, wherein said carrier comprises an adhesive. 6. A device of claim 1, wherein the ratio of the distance between the first conductive electrode and the second conductive electrode and the distance between the first conductive electrode and the barrier membrane contacting surface is at least about 0.1. 7. A device of claim 1, wherein the ratio of the distance between the first conductive electrode and the second conductive electrode and the distance between the first conductive electrode and the barrier membrane contacting surface is at least about 5. 8. A device of claim 1, wherein said power source produces a voltage from about 0.1 to about 9 volts. 9. A device of claim 1, wherein said device produces a current density of less than about 0.5 mA/cm2. 10. A device having a barrier membrane contacting surface, said device comprising: a first conductive electrode; a second conductive electrode; and a reservoir; wherein said first conductive electrode and said second conductive electrode are arranged such that they are both capable of being in ionic communication with a carrier upon the inclusion of said carrier to said reservoir, and wherein the difference of the standard potentials of said first conductive electrode and said second conductive electrode is at least 0.2 V and wherein the electrons that pass between said first conductive electrode and said second conductive electrode are generated as a result of said difference of the standard potentials. 11. A method of treating a skin condition, said method comprising applying to said skin a device of claim 1. 12. A method of claim 11, wherein said skin condition is acne or rosacea. 13. A method of claim 11, wherein said skin condition is a skin infection. 14. A method of claim 11, wherein said skin condition is excess or insufficient sebum secretion. 15. A method of claim 11, wherein said skin condition is excess or insufficient skin pigmentation. 16. A method of claim 11, wherein said skin condition is folliculitis or pseudo-folliculitis barbae. 17. A method of claim 11, wherein said skin condition is pain. 18. A method of claim 11, wherein said skin condition is wrinkles or sagging skin. 19. A method of treating a skin condition, said method comprising applying to said skin a device of claim 10. 20. A method of claim 19, wherein said skin condition is acne or rosacea. 21. A method of claim 19, wherein said skin condition is a skin infection. 22. A method of claim 19, wherein said skin condition is excess or insufficient sebum secretion. 23. A method of claim 19, wherein said skin condition is excess or insufficient skin pigmentation. 24. A method of claim 19, wherein said skin condition is folliculitis or pseudo-folliculitis barbae. 25. A method of claim 19, wherein said skin condition is pain. 26. A method of claim 19, wherein said skin condition is wrinkles or sagging skin.
BACKGROUND OF THE INVENTION [0002] Transdermal devices have been widely prescribed for decades in the treatment of is systemic diseases and local conditions. During passive transdermal delivery, an active agent is delivered into a mammal by using a concentration gradient across a barrier membrane (e.g., through passive diffusion through skin). For example, a patch containing the drug in high concentration is affixed to the skin of a patient. [0003] Electricity may be employed to facilitate drug transport across the skin barrier. In electricity-assisted devices, an electric potential (voltage) is applied to the membrane to facilitate drug transport. In transdermal iontophoresis, an ionized drug migrates into the skin driven by an applied electric potential gradient. Anionic drugs are delivered into the skin under the cathode (negatively charged electrode), while cationic drugs are delivered under the anode (positively charged electrode). Iontophoresis enables enhanced as well as better control of permeation rate of the ionic species into the skin. [0004] The most common design of an iontophoresis device includes a power source (e.g., a battery), an electric control mechanism, and two separate conductive electrodes. Each conductive electrode is in contact with a separate electrolyte composition (with or without an active agent). The electrolyte or ionic active composition is generally either an aqueous solution contained in a liquid chamber or a semi-solid. The assembly of the conductive electrode and electrolyte composition is often referred to as “an electrode assembly” or simply “an electrode.” The two electrode assemblies are usually affixed to the skin separated by electric insulation between them. [0005] Alternatively, the two electrode assemblies may be constructed into a single iontophoresis device with an electric insulating material built between the two electrode assemblies for electrical isolation to prevent shorting current. An example of such an iontophoresis device is disclosed in U.S. Pat. No. 5,387,189. [0006] In another variation of the common iontophoresis device designs, the electrolyte composition in one of the two electrode assemblies is eliminated, and the conductive electrode is placed directly in contact with the skin to complete the electric circuit. An example of such iontophoresis device is disclosed in U.S. Pat. No. 6,385,487. [0007] During a typical iontophoresis operation (mono-polar operation), one of the two electrodes (i.e., active electrode) drives the active agent into the skin. The other electrode (i.e., disperse electrode) serves to close the electrical circuit through the skin. Sometimes, a second active agent of opposite electric charge can be placed into electrolyte composition in contact with the second electrode, thus, being delivered into the skin under the second electrode. Alternatively, the electric polarity of the first and second electrodes can be reversed periodically to drive ionic species under both electrodes (bi-polar operation). A bi-polar iontophoresis device for transdermal drug delivery is disclosed U.S. Pat. No. 4,406,658. [0008] Using a galvanic couple as the power source in iontophoresis device is well known in the art. See e.g., U.S. Pat. Nos. 5,147,297, 5,162,043, 5,298,017, 5,326,341, 5,405,317, 5,685,837, 6,584,349, 6,421,561 and 6,653,014. Typical materials from which a galvanic couple is made includes a zinc donor electrode and a silver chloride counter electrode. Such a combination produces an electric potential of about one volt. Such a galvanic couple powered iontophoresis system, absent some controlling means, activates automatically when body tissue and/or fluids form a complete circuit with the system to generate the electricity. SUMMARY OF THE INVENTION [0009] In one aspect, the present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a reservoir; wherein said power source is in electric communication with said first conductive electrode and said second conductive electrode, wherein said first conductive electrode and said second conductive electrode are arranged such that they are both capable of being in ionic communication with a carrier upon the inclusion of said carrier into said reservoir; and the use thereof. [0010] In one aspect, the present invention features a method of exfoliating the skin by applying to skin in need of such exfoliating a device including a housing having a skin contacting surface, a first conductive electrode, a second conductive electrode, and a carrier including an agent selected from an alpha-hydroxy acid, beta-hydroxy acid, and salts thereof; wherein the first conductive electrode is in electric communication with the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the carrier is in communication with the skin contacting surface, and wherein the skin contacting surface is placed in contact with the skin. [0011] In another aspect, the present invention features a method of exfoliating the skin by topically applying a composition including a first conductive electrode in the form of a particulate, a second conductive electrode in the form of a particulate, and an agent selected from an alpha-hydroxy acid, beta-hydroxy acid, and salts thereof wherein the difference of the standard potentials of the first conductive electrode and the second conductive electrode is at least 0.2 V. [0012] In another aspect, the present invention features a method of promoting a composition including a first conductive electrode in the form of a particulate and a second conductive electrode in the form of a particulate wherein the difference of the standard potentials of the first conductive electrode and the second conductive electrode is at least 0.2 V, such method including promoting the topical application of such composition for the treatment of a wound on barrier membrane. [0013] In another aspect, the present invention features a method of treating pores on the skin by applying to skin in need of such treatment a device including a housing having a skin contacting surface, a first conductive electrode, a second conductive electrode, and a carrier; wherein the first conductive electrode is in electric communication with the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the carrier is in communication with the skin contacting surface, wherein the skin contacting surface is placed in contact with the skin, and wherein and wherein said method of treating pores on the skin is selected from the group of cleansing pores on the skin, reducing sebum on the skin, reducing the appearance of blackheads on the skin, and reducing the appearance of pores on the skin. [0014] In another aspect, the present invention features a method of treating pores on the skin by topically applying a composition including a first conductive electrode in the form of a particulate and a second conductive electrode in the form of a particulate, wherein the difference of the standard potentials of the first conductive electrode and the second conductive electrode is at least 0.2 V. [0015] In another aspect, the present invention features a method of promoting a composition including a first conductive electrode in the form of a particulate and a second conductive electrode in the form of a particulate wherein the difference of the standard potentials of the first conductive electrode and the second conductive electrode is at least 0.2 V, such method including promoting the topical application of such composition for the treatment of pores on the skin, wherein the method of treating pores on the skin is selected from the group of cleansing pores on the skin, reducing sebum on the skin, reducing the appearance of blackheads on the skin, and reducing the appearance of pores on the skin. [0016] In one aspect, the present invention features a method of treating infections of the skin, including but not limited to, acne or rosacea, by applying to the skin electrochemically generated zinc ions. In one embodiment, the method includes topically applying a device including an anode containing zinc. In a further embodiment, the device includes a housing having a skin contacting surface; a first conductive electrode containing zinc; a second conductive electrode; and a carrier; wherein the first conductive electrode is in electric communication with the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, and wherein the carrier is in communication with said skin contacting surface. [0017] In another aspect, the present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a carrier; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode and the second conductive electrode are in ionic communication with the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface. In another aspect, the present invention features a method of administering electricity to a human barrier membrane by applying to the membrane such a device. In another aspect, the present invention features a method of treating a skin condition by applying to the skin such a device. [0018] In another aspect, the present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; and a carrier containing an active agent; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode and the second conductive electrode are in ionic communication with the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface. In another aspect, the present invention features a method of administering electricity to a human barrier membrane by applying to the membrane such a device. In another aspect, the present invention features a method of treating a skin condition by applying to the skin such a device. [0019] In another aspect, the present invention features a device having a barrier membrane contacting surface, the device containing: a power source; a first conductive electrode; a second conductive electrode; a first light emitting diode; and a carrier containing an active agent; wherein the power source is in electric communication with the first conductive electrode, the second conductive electrode, and the light emitting diode, and wherein the device is arranged such that light from the first light emitting diode and the carrier are in communication with the barrier membrane contacting surface. In another aspect, the present invention features a method of administering an active agent to a human barrier membrane by applying to the membrane such a device. In another aspect, the present invention features a method of treating a skin condition by applying to the skin such a device. [0020] In another aspect, the present invention features a method of treating a skin condition by applying to the skin a device having a barrier membrane contacting surface that administers an oxidizing agent to the barrier membrane, wherein the device contains: a power source; a first conductive electrode, wherein the first conductive electrode is an inert anode; a second conductive electrode, wherein the second conductive electrode is a cathode; and a carrier containing water; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the oxidizing agent is generated by electric current passing from the first conductive electrode through the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface. In another aspect, the present invention features a method of administering an oxidizing agent to a barrier membrane by applying to the membrane such a device. [0021] In another aspect, the present invention features a method of treating a skin condition by applying to the skin a device having a barrier membrane contacting surface that administers a reducing agent to the barrier membrane, wherein the device contains: a power source; a first conductive electrode, wherein the first conductive electrode is an inert cathode; a second conductive electrode, wherein the second conductive electrode is a anode; and a carrier containing water; wherein the power source is in electric communication with the first conductive electrode and the second conductive electrode, wherein the first conductive electrode is in ionic communication with the carrier, wherein the reducing agent is generated by electric current passing from the first conductive electrode through the carrier, and wherein the carrier is in communication with the barrier membrane contacting surface. In another aspect, the present invention features a method of administering an reducing agent to a barrier membrane by applying to the membrane such a device. [0022] Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.
DETAILED DESCRIPTION OF THE INVENTION [0038] It is believed that one skilled in the art can, based upon the description herein, utilize the present invention to its fullest extent. The following specific embodiments are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. [0039] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference. Unless otherwise indicated, a percentage refers to a percentage by weight (i.e., %(W/W)). [0040] What is meant by a “product” is a product containing the device in finished packaged form. In one embodiment, the product contains instructions directing the user to apply the device to the barrier membrane (e.g., to treat a skin condition). Such instructions may be printed on the device, label insert, or on any additional packaging. [0041] In one aspect, the present invention features promoting a device of the present invention for its intended use. What is meant by “promoting” is promoting, advertising, or marketing. Examples of promoting include, but are not limited to, written, visual, or verbal statements made on the product or in stores, magazines, newspaper, radio, television, internet, and the like. [0042] As used herein, “pharmaceutically-acceptable” means that the ingredients which the term describes are suitable for use in contact with the barrier membrane (e.g., the skin or mucosa) without undue toxicity, incompatibility, instability, irritation, allergic response, and the like. [0043] As used herein, “safe and effective amount” means an amount of the ingredient or of the composition sufficient to provide the desired benefit at a desired level, but low enough to avoid serious side effects. The safe and effective amount of the ingredient or composition will vary with the area being treated, the age and skin type of the end user, the duration and nature of the treatment, the specific ingredient or composition employed, the particular pharmaceutically-acceptable carrier utilized, and like factors. [0044] As used herein, the term “treating” or “treatment” means the treatment (e.g., alleviation or elimination of symptoms and/or cure) and/or prevention or inhibition of the condition (e.g., a skin, mucosal, or nail condition). What is meant by a “skin condition” is a dermatological disease or disorder (including, but not limited, acne, rosacea, or skin infections) or skin characteristic (including, but not limited to, pigmentation, hair growth regulation, skin texture, skin firmness, skin elasticity, skin vasculature, dark circles, cellulite, sebum regulation (e.g., increasing or decreasing sebum production), pore size and appearance, hydration of dermal and epidermal tissues, skin shine, dandruff, body odor, diaper rash, scarring, pain, itch, inflammation, and edema. Examples of skin, mucosal or nail infections include, but are not limited to, those due to susceptible pathogens such as acne, rosacea, impetigo, folliculitis, furunculosis, ecthyma, eczema, psoriasis, atopic dermatitis, herpes, epidermolysis bullosa, iethyosis, and infected traumatic lesions (e.g., ulcers, minor burns, cuts, abrasions, lacerations, wounds, biopsy sites, surgical incisions and insect bites), cold sores, canker sores, periodontal diseases, vaginal fungal, bacterial and/or viral infections, and nail fungal and/or bacterial infections. [0045] The present invention relates to a device for the delivery of electricity (e.g., to induce a desirable biological response) and/or an active agent into a barrier membrane. In one embodiment, the device of the present invention is a self-contained device containing a battery as power source and two conductive electrodes in electric communication with the positive and negative poles of the battery. In one embodiment, the device of the present invention is a self-contained device containing at least a pair of two dissimilar conductive electrodes in electric communication as a power source. By “electric communication” is meant that electrons can directly pass between the elements of the device (e.g., between the conductive electrodes of the device). In one embodiment, the two conductive electrodes are in electric communication via direct contact with each other. [0046] By “ionic communication” it meant that electrons can pass between the elements (e.g., the conductive electrode, the carrier and/or the conductive electrode and the skin) through the migration of ions as “electron movers” in contact with such elements (e.g., electrons pass between the conductive electrode and the skin via ionic transport of electrolytes (e.g., in the carrier) in contact with the conductive electrode and the skin). [0047] In one embodiment, the two conductive electrodes are in ionic communication with the carrier containing an electrolyte (e.g., ions of one or more electrolytes in the carrier are in contact with the conductive electrode) and the carrier is in ionic communication with the skin. This electrode configuration differs from those in conventional iontophoresis devices in which each conductive electrode is in contact with a separate carrier (e.g., each electrode is contained in a separate compartment and affixed to the skin with electric insulation between them in order that all the electric current travels through the skin to complete the electric circuit). An advantage of such an embodiment of the present invention includes the capability of delivering simultaneously active agents of opposite charges from the same carrier into substantially the same skin site under the conductive electrodes. Another advantage is that the devices of the present invention are much easier to manufacture than conventional iontophoresis devices, and therefore, are enable substantial cost-savings. Another advantage is that the devices may be more versatile in its shape, thus increasing significantly their utility. [0048] The device contains a barrier membrane contacting surface (e.g., a skin contacting surface) that is applied to the membrane (e.g., applied by the user to the user's skin). The device is arranged such that carrier is in communication with the barrier membrane contacting surface (e.g., such that electricity and/or the active agent may be administered from the carrier into the barrier membrane). In one embodiment, the carrier is the barrier membrane contacting surface (e.g., the carrier is a hydrogel). In one embodiment, the device contains a light emitting diode such that light from the light emitting diode is in communication with the barrier membrane contacting surface (e.g., such that the light may be administered to the barrier membrane). [0049] In one embodiment, the device of the present invention delivers an active agent into the barrier membrane. The active agents to be delivered by the device of the present invention include active agents either initially incorporated in the carrier or electrochemically generated by the electric current passing from a conductive electrode through the carrier during use. What is meant by “electrochemically generated” is that the chemical specie is created as a result of an electrochemical reaction resulting from electric current flowing through an electrode, such a chemical specie released from a reactive electrode (e.g., an electrochemically generated zinc ion such as those generated by a zinc positive electrode), a chemical specie electrochemically generated on the surface of an inert electrode, or a chemical specie that is a subsequent reaction product of such electrochemically generated specie (e.g., a pH change from water electrolysis results in the release of active agents or desirable barrier membrane responses). [0000] Power Source [0050] In one embodiment, the device of the present invention includes a power source. The power source may be conventional direct current (DC) or pulsed DC, such as that disclosed in U.S. Pat. No. 5,042,975. In one embodiment, the current density to be used by the device in the present invention (current intensity per unit area of the barrier membrane) is generally less than about 0.5 mA/cm2, such as less than about 0.1 mA/cm2 or less than about 0.05 mA/cm2. In one embodiment, the power source produces a voltage of from about 0.1 volts to about 9 volts, such as from about 1 to about 3 volts, such as about 1.5 volts. In another embodiment, the power source is connected to a voltage boosting/current regulating circuit that is capable of supplying a voltage up to 50 volts in order to provide a constant current output for the device. [0051] In one embodiment, the power source is a battery (e.g., a rechargeable or disposable battery). In one embodiment, the battery is a disposable battery of small size suitable for a wearable patch or facial mask type adhesive device. Examples of suitable batteries include, but not limited to, button or coin batteries such as silver oxide, lithium, and zinc air batteries (which are typically used in small electronic devices). A zinc air battery is preferred because of its small size and high energy density, as well as its environmental friendliness. Examples of zinc air batteries include, but are not limited to, Energizer™ AC5 and AC10/230 (Eveready Battery Co. Inc., St. Louis, Mo.) or their equivalents. Another preferred battery for the device is a flexible thin layer open liquid state electrochemical cell battery, such as a battery described in U.S. Pat. No. 5,897,522 and U.S. Patent Application No. 20030059673A1. In another embodiment, the power source is a rechargeable battery, such as a Ni—Cd, Ni-MH, or Li-Ion rechargeable battery well known in the art. In another embodiment, the power source is a rechargeable supercapacitors, such as described in U.S. Pat. No. 6,552,895 and U.S. Pat. No. 6,275,372. In another embodiment, the device is re-useable. For example, the device may comprises a re-useable part (e.g., a power source and electrodes) and a disposable part (e.g., the reservoir, electrodes and/or carrier). [0000] Galvanic Couple [0052] In one embodiment, the device/composition of the present invention has a galvanic couple as its power source, wherein the electrons that pass between the first conductive electrode and the second conductive electrode are generated as a result of the difference of the standard potentials between the electrodes (e.g., the electricity is not generated by an external battery or other power source such as an AC power source). Examples of such galvanic couples include, but are not limited to, zinc-copper, zinc-copper/copper halide, zinc-copper/copper oxide, magnesium-copper, magnesium-copper/copper halide, zinc-silver, zinc-silver/silver oxide, zinc-silver/silver halide, zinc-silver/silver chloride, zinc-silver/silver bromide, zinc-silver/silver iodide, zinc-silver/silver fluoride, zinc-gold, magnesium-gold, aluminum-gold, magnesium-silver, magnesium-silver/silver oxide, magnesium-silver/silver halide, magnesium-silver/silver chloride, magnesium-silver/silver bromide, magnesium-silver/silver iodide, magnesium-silver/silver fluoride, magnesium-gold, aluminum-copper, aluminum-silver, aluminum-silver/silver oxide, aluminum-silver/silver halide, aluminum-silver/silver chloride, aluminum-silver/silver bromide, aluminum-silver/silver iodide, aluminum-silver/silver fluoride, copper-silver/silver halide, copper-silver/silver chloride, copper-silver/silver bromide, copper-silver/silver iodide, copper-silver/silver fluoride, iron-copper, iron-copper/copper oxide, iron-copper/copper halide, iron-silver, iron-silver/silver oxide, iron-silver/silver halide, iron-silver/silver chloride, iron-silver/silver bromide, iron-silver/silver iodide, iron-silver/silver fluoride, iron-gold, iron-conductive carbon, zinc-conductive carbon, copper-conductive carbon, magnesium-conductive carbon, and aluminum-carbon. The materials which serve to make up the galvanic couple may also serve as the connecting lead wires as well as the conductive electrodes of the device, e.g., zinc as the conductive anode and silver/silver chloride as the conductive cathode or zinc as the conductive anode and copper as the conductive cathode. The metals serve as the galvanic couple and conductive electrodes may also be alloys. Non-limiting examples of the alloys include alloys of zinc, copper, aluminum, magnesium as anode materials, and alloys of silver, copper, gold as cathode materials. [0053] In one embodiment, the conductive electrode may be made of metal/metal or metal/nonmetal composite (e.g., held together by polymeric binders). Non-limiting examples of such composite conductive electrodes include (i) electrodes made of powders or flakes of silver, silver chloride, optional conductive carbon, and polymeric binders (e.g., dried coating of conductive silver/silver chloride ink) and (ii) electrodes made of powders or flakes of zinc, optional conductive carbon, and polymeric binders (e.g., dried coating of conductive zinc ink). [0054] In one embodiment, the materials that make up the galvanic couple have a standard potential difference equal to or greater than about 0.1 volts, such as greater than about 0.2 volts such as greater than about 0.5 volts. In one embodiment, the materials that make up the galvanic couple have a standard potential difference equal to or less than about 3 volts. [0055] In one embodiment, the device or composition of the present invention generates and/or is capable of generating current into the barrier membrane (i.e., current density) of from about 1 nano-A/cm2 to about 500 micro-A/cm2 of electricity such as from about 100 nano-A/cm2 to about 50 micro A/cm2. [0056] In one embodiment, one of the conductive electrodes is in the form of a metal sheet, a metal wire, or a metal coated on a substrate (e.g., a metal or non-metal substrate such as a polymer, natural or synthetic fiber or fabric), and the other conductive electrode is attached or deposited to the other conductive electrode by means known in the arts, including, but not limited to, electroplating, electroless plating, binding with binders (e.g., conductive inks), plasma deposition, and combination thereof. In a further embodiment, the metal sheet is perforated. In one embodiment, such perforated metal sheet is in the form of a mesh such as a mesh of zinc, magnesium, aluminum, copper, or their alloys thereof. In one embodiment, the second conductive electrode is in the form a fabric coated with a metal, and its oxide, halide, and sulfide, such as a fabric coated with silver, silver/silver oxide, silver/silver halide, zinc, magnesium, copper, copper/copper halide, copper/copper oxide. In another embodiment, the second conductive electrode is deposited to the first conductive electrode by chemical or electrochemical deposition such as electroless plating for chemical deposition and electroplating for electrochemical deposition as known in the art. In a further embodiment, the second conductive electrode is deposited to the first conductive electrode by physical deposition, such as spray coating, plasma coating, conductive ink coating, screen printing, dip coating, or vacuum deposition. [0057] In one embodiment, the device is a single compartment treatment device. What is meant by a “single compartment treatment device” is a device in which both conductive electrodes of the device are in contact with the same carrier. Examples of such devices are shown in FIGS. 1-4 and 6-11. [0000] Carrier [0058] The carrier of the present invention is a liquid (e.g., a solution, a suspension, or an emulsion which may be immobilized within an absorbent material such as gauze or non-woven pad), a semi-solid (e.g., a gel, a cream, a lotion, microemulsion, or hydrogel), or a solid (e.g., a lyophilized composition containing active agents, which may be reconstituted by adding a liquid prior to use) that during use is capable of conducting electricity from a conducting electrode (e.g., the carrier contains one or more electrolytes, organic solvents, and water). [0059] In one embodiment, the carrier (e.g., a liquid or semi-solid) is added to the device by the user prior to applying the device to the barrier membrane. For example, the carrier is added to a reservoir in the device such that upon addition into the reservoir, both the conductive electrodes (e.g., the anode and the cathode) are in ionic communication with the carrier (e.g., the conductive electrodes are within or in contact with the reservoir). In one embodiment, the reservoir is a chamber containing the electrodes or an absorbent material that can immobilize the carrier (such as gauze or non-woven pad) that contains or is in contact with the electrodes (e.g., the electrodes are contained within or affixed to the absorbent material. [0060] In one embodiment, the carrier is manufactured and placed in storage as a stable nonconductive composition (e.g., an anhydrous composition with negligible conductive ions). Prior to or during the use, as an activation step, water is mixed into the anhydrous composition to significantly increase its conductivity by enabling the passage of an electric current through the system. Examples of the carrier include, but are not limited to, skin creams, lotions, shampoos, moisturizers, skin toners, and cleansers. Other examples of carriers include biological fluids or excretion such as sweat, skin moisture, interstitial fluid, intercellular fluid, intracellular fluid, wound exudates, blood, saliva, menstrual fluid, tears, urine, and vaginal fluid that exit the body and enter into the reservoir of the device. [0061] Examples of electrolytes include, but are not limited to, pharmaceutically acceptable organic and organic acids, bases, salts, buffers, peptides, polypeptides, proteins, nucleic acids, and/or other inorganic and organic compounds. Examples of salts include, but are not limited to, chloride salts (such as sodium chloride, potassium chloride, lithium chloride, calcium chloride, strontium chloride, magnesium chloride or other chloride salts), as well as salts of sodium, potassium, lithium, calcium, magnesium, strontium, fluoride, iodide, bromide. Examples of buffers include, but are not limited to, phosphates, citrates, acetates, lactates, and borates. [0062] In one embodiment, the electrolyte is an active agent, or becomes an active agent after the passage of the electric current through the carrier. Examples of such electrolyte-active agents include, but are not limited to, salicylic acid, salicylates, and other weak acid or weak base active agents. [0063] In one embodiment, the carrier contains water. In a further embodiment, the carrier may also contain one or more organic solvents. Examples of organic solvents include, but are not limited to: dimethyl isosorbide; isopropylmyristate; surfactants of cationic, anionic and nonionic nature; vegetable oils; mineral oils; waxes; gums; synthetic and natural gelling agents; alkanols; glycols; and polyols. [0064] Examples of glycols include, but are not limited to, glycerin, propylene glycol, butylene glycol, pentalene glycol, hexylene glycol, polyethylene glycol, polypropylene glycol, diethylene glycol, triethylene glycol, glycerol, and hexanetriol, and copolymers or mixtures thereof. Examples of alkanols include, but are not limited to, those having from about 2 carbon atoms to about 12 carbon atoms (e.g., from about 2 carbon atoms to about 4 carbon atoms), such as isopropanol and ethanol. Examples of polyols include, but are not limited to, those having from about 2 carbon atoms to about 15 carbon atoms (e.g., from about 2 carbon atoms to about 10 carbon atoms) such as propylene glycol. [0065] The organic solvents may be present in the carrier in an amount, based upon the total weight of the carrier, of from about 1 percent to about 90 percent (e.g., from about 5 percent to about 50 percent). Water may be present in the carrier (prior to use) in an amount, based upon the total weight of the carrier, of from about 5 percent to about 95 percent (e.g., from about 50 percent to about 90 percent). [0066] In one embodiment, the carrier is a nonconductive carrier such as an anhydrous composition that contains organic solvents that interact strongly when mixed with water during the application, resulting in the release of salvation heat to increase the temperature of the carrier and/or the power source, consequently increasing the electric current generated by either the battery or the galvanic power source. Examples of such organic solvents include, but are not limited to, glycerol, glycols (e.g., propylene glycol, butylenes glycol and ethylene glycol) and polyglycols (e.g., polyethylene glycols of various molecular weight, such as PEG400 and polypropylene glycols of various molecular weights). [0067] The carrier may also contain: preservatives (such as cresol, chlorocresol, benzyl alcohol, methyl p-hydroxylbenzoate, propyl p-hydroxybenzoate, phenol, thimerosal, benzalkonium chloride, benzethonium chloride, and phenylmercuric nitrate); stabilizing agents or antioxidants (such as ascorbic acid, ascorbic acid esters, butylhydroxy anisole, butylhydroxy toluene, cysteine, N-acetylcysteine, sodium bisulfite, sodium metabisulfite, sodium formaldehydesulfoxylate, acetone sodium bisulfite, tocopherols, and nordihydroguaiaretic acid); chelating agents (such as ethylenediaminetetraacetic acid and its salts); buffers (such as acetic acid, citric acid, phosphoric acid, glutamic acid, and salts thereof); and tonicity adjusting agents (such as sodium chloride, sodium sulfate, dextrose and glycerin). [0068] In one embodiment, the carrier may also contain a suspending material and/or a fluid-absorbing material (e.g., for physically stabilizing the ingredients of the carrier). Examples of suspending materials include, but are not limited to: cotton-based gauze; non-woven pads made of rayon or a mixture of rayon, polyester and/or other polymer fibers; open-cell foam and sponge-like materials contained of polyurethane, polyester and/or other polymers; and cross-linked and noncross-linked gelling materials, such as polyacrylamide, polyvinyl alcohol, gelatin, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and carboxymethylcellulose. [0069] Examples of fluid-absorbing materials include, but are not limited to: cross-linked and non-cross-linked polymers; swellable polymers such as water-swollen cellulose derivatives (e.g., methylcellulose (MC), hydroxyethyl methylcellulose (HEMA), hydroxypropyl methylkcellulose (HPMC), ethylhydroxyethyl cellulose (EHEC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), and carboxymethlcellulose (CMC) and their salts); polyvinyl alcohol (PVA); polyvinylpyrrolidone (PVP); polyethylene oxide (PEO); polymers prepared by monomers such as hydroxyethyl methacrylate (HEMA), hydroxyethoxyethyl emthacrylate (HEEMA), hydroxydiethoxyethl methacrylate (HDEEMA), methyoxyethyl methacrylate (MEMA), methoxyethoxyethyl methacrylate (MEEMA), methyldiethoxyethyl methacrylate (MDEEMA), ethylene glycol dimethacrylate (EGDMA), n-vinyl-2pyrrolidone (NVP), methacrylic acid (MA), and vinyl acetate (VAC); polycrylamide; gelatin; gums and polysaccharides such as gum arabic, gum karaya, gum tragacanth, guar gum, gum benzoin, and alginic acid and their salts; polyethylene glycol (PEG); polypropylene glycol (PPG); and clays or other swellable minerals such as bentonite and montmorillonite. The amount of fluid absorbable material in the carrier may range from about 0.1% to about 95%, by weight, such as from about 1% to about 20%, by weight, of the carrier. [0070] Another embodiment of the present invention is directed to pairing one or more inert conductive electrodes in order to electrochemically generate oxidizing or reducing agents from electrochemically reactive materials in situ in the carrier. Such oxidizing or reducing agents can be used as active agents to treat barrier membrane conditions. [0071] Examples of the electrochemically reactive materials in the carrier according to the present invention include, but are not limited to, water and compounds containing the elements selected from the Periodic Table of the Elements VIIB and VIIB (such as oxygen, sulfur, fluorine, chlorine, bromine, and iodine). [0072] In one embodiment, the reactive material reacts with the inert anode to form an oxidizing agent. Examples of such a reactive material includes, but is not limited to, the ions OH−, Cl−, I−, Br−, SO3 2−, and HCO3 −. The present device, thus, enables to generation of oxidizing agents, such as nascent oxygen (e.g., singlet oxygen), chlorine and chlorine dioxide gases, which are difficult to formulate in a conventional topical product. [0073] In one embodiment, the reactive material reacts with the inert cathode to form a reducing agent. Examples of such a reactive material includes, but is not limited to, oxidized or disulfide forms of thio-compounds with one or more sulfhydryl functional groups, thio-containing amino acids and their salts or esters, and sulfides. Examples of such thio-compounds include, but are not limited to: thioglycolic acid and its salts, such as thioglycolates of calcium, sodium, strontium, potassium, ammonium, lithium, magnesium, and other metal salts; thioethylene glycol; thioglycerol; thioethanol; thioactic acid; and thiosalicylic acid; and their salts. Examples of the thio-containing amino acids include, but are not limited to, L-cysteine, D-cysteine, DL-cysteine, N-acetyl-L-cysteine, DL-homocysteine, L-cysteine methyl ester, L-cysteine ethyl ester, N-carbamoyl cysteine, glutathione, and cysteamine. Examples of sulfides, include but are not limited to, calcium, sodium, potassium, lithium and strontium sulfides and glutathione disulfide. The inert cathode converts the aforementioned reactive oxidized or disulfide form of a sulfur-containing compound to a thio-containing compound, or a sulfydryl-containing compound. Examples of such a conversion is the conversion of cystine to cysteine and the conversion of the oxidized form of glutathione to glutathione. [0074] In one embodiment, the concentration of the reactive material in the carrier may range from about 0.01% to about 25%, by weight, such as from about 0.1% to about 10%, by weight, of the carrier. The pH value of the carrier may range from about pH 1.5 to about pH 9, preferably from pH 2 to pH 7, and most preferably from about pH 3 to pH 5. [0075] In one embodiment, the carrier contains an adhesive. The adhesive is used to affix the device to the barrier membrane. Examples of hydrophobic adhesives include, but are not limited to, silicones, polyisobutylenes and derivatives thereof, acrylics, natural rubbers, and combinations thereof. Examples of silicone adhesives include, but are not limited to, Dow Corning 355 available from Dow Corning of Midland, Mich.; Dow Corningo X7-2920; Dow Corning X7-2960; and GE 6574 available from General Electric Company of Waterford, N.Y. Examples of acrylic adhesives include, but are not limited to, vinyl (D acetate-acrylate) multipolymers such as Gelva 7371, available from Monsanto Company of St. Louis, Mo.; Gelvao 7881; Gelva 2943; and 1-780 medical grade adhesive available from Avery Dennison of Painesville, Ohio. Examples of hydrophilic adhesives include, but are not limited to, gum papaya and other natural gums, MC, HEMA, HPMC, EHEC, HEC, HPC, CMC, PVA, PVP, PEO, HEMA, HEEMA, HDEEMA, MEMA, MEEMA, MDEEMA, EGDMA, NVP MA, VAC, polycrylamide. getatins, gum arabic, gum karaya, gum tragacanth, guar gum, gum benzoin, and alginic acid and their salts, polyethylene glycol (PEG), and polypropylene glycol (PPG). [0076] In one embodiment, the concentration of the adhesive in the carrier may range from about 0.1% to about 95%, by weight, such as from about 1% to about 20%, by weight, of the carrier. [0000] Electrodes [0077] The conductive electrodes of the present invention may be a reactive conductive electrodes or inert conductive electrodes. What is meant by a “reactive conductive electrode” is that the conductive electrode itself goes through a change in its chemical composition during the electrode chemical reactions occurring with the electric current passing through the electrode during the process. In one embodiment, the reactive conductive electrode is an anode made of reactive materials such as a pure metal or a metal alloy including, but not limited to, zinc, aluminum, copper, magnesium, manganese, silver, titanium, tin, iron, and alloys thereof. The materials which serve to make up the galvanic couple described earlier may also serve as the reactive conductive electrode. Upon passage of an electric current, metal ions such as zinc, copper, magnesium, manganese and/or aluminum cations are released from the anode into the carrier and delivered into the barrier membrane. Such ions may serve therapeutic benefits such as anti-microbial effects, immunologic modulation, enzymatic regulation, and/or anti-inflammatory effects. [0078] In one embodiment, the reactive conductive electrode is made of reactive materials such as metal halides (e.g., silver-silver chloride (Ag/AgCl), silver-silver bromide, and silver-silver iodide). In this case, the primary electrochemical reaction at the cathode surface is conversion of solid silver halide to metallic silver with little unwanted consumption of the oxidizing agents generated by the anode. The released halide ions may be subsequently oxidized to oxidizing agents, such as chloride ions to chlorine (Cl2), hypochlorous acid (HClO), and hypochlorite ions (ClO−), and iodide ions to iodine. [0079] What is meant by an “inert conductive electrode” is that the conductive electrode itself does not go through a change in its chemical composition. In one embodiment, the anode is made of an inert conductive electrode, so that the electrochemical process at the surface of the anode generates oxidizing agents such as nascent oxygen (e.g., by electrolysis of water) and/or chlorine-containing oxidizing agents such as chlorine, hypochlorite, chlorate and perchlorate, and chlorine dioxide. Nascent oxygen is an oxidizing agent that is inhibitive to P. acnes, and chlorine-containing oxidizing agents are potent antimicrobial agent with bacteriacidal activity. [0080] In one embodiment, the conductive electrode is made of, or coated on the surface of, an inert materials such as noble metals (e.g., gold, platinum, or gold-coated conductive metals), conductive carbon (e.g., glassy carbon or graphite), carbon-embedded polymers (e.g., carbon silicone rubbers), conductive carbon polymer foam or sponge, silver halide-coated silver (e.g., silver chloride-coated silver, silver bromide-coated silver, and silver iodide-coated silver), or corrosive resistant alloys. In another embodiment, a conductive electrodes is in the form of a metal sheet, a metal wire, or a metal coated on a metal or nonmetal substrate (e.g., a polymer, natural or synthetic fiber or fabric), or is made by attaching or depositing a conductive electrode material to conductive or nonconductive substrate of a desired size and shape, such as by electroplating, electroless plating, binding with binders (e.g., conductive inks), plasma deposition, spray coating, plasma coating, conductive ink coating, screen printing, dip coating, or vacuum deposition, and combinations thereof). [0081] In one embodiment, the anode of the device, serving as the conductive electrode, is made of aforementioned reactive conductive oxidizable metals such as zinc, calcium, magnesium, aluminum, iron, tin, copper, or alloys thereof, while the cathode, also serving as the conductive electrode, is made of the aforementioned reactive reducible conductive materials such as a more chemically stable metal and its metal halides, oxide, sulfide or other metal salts, such as silver and silver halides (e.g., silver chloride, silver bromide, silver iodide, silver fluoride), silver oxide, silver sulfide. In one embodiment, the reducible conductive material is in direct contact with a good electric conductor, such as: a thin layer of silver chloride, silver oxide, or silver sulfide over metallic silver; silver chloride powder with a binder (e.g., silver chloride ink); and/or silver chloride powder mixed with silver or conductive carbon powder held together by a binder in a matrix form (e.g., silver-silver chloride ink and silver chloride-carbon ink). [0082] In another embodiment, the anode of the device in the present invention is made of aforementioned reactive conductive oxidizable metals while the cathode is made of aforementioned more chemically stable electrode materials such as conductive carbon, metallic silver, gold or platinum, or a powder mixture of conductive carbon and the noble metal in a matrix form as disclosed in U.S. Pat. No. 5,162,043. [0083] In one embodiment, the device of the present invention enables the targeted delivery of beneficial zinc through hair follicles to the pilosebaceous unit (i.e., a sebaceous gland and the associated hair follicle) to treat acne or rosacea. Zinc is an essential metal to the human body because it participates in various biological activities in the body (e.g., the body of a 70-Kg person contains about 2.3 grams of zinc). It is known that the lack of zinc in the body may lead to skin diseases such as acne. [0084] In another embodiment, the device of the present invention enables the targeted delivery of other beneficial metals into the hair follicles and the pilosebaceous glands by using an anode made of zinc alloy containing small quantities of other beneficial metals. Such beneficial metals includes, without limitation, certain metals essential to the human body such asiron, copper, magnesium, manganese, calcium, potassium, aluminum, and selenium. As the zinc alloy anode oxidizes, it releases into the carrier zinc ions and other beneficial metals in the zinc alloy, which ingredients subsequently migrate into the hair follicles under the applied electric potential over the skin. In one embodiment, the content of the zinc alloy in the anode is greater than about 50% by weight, such as greater than 90% by weight. [0085] In one embodiment, the ratio of the conductance measured between the first conductive and second conductive electrode of (i) the carrier and (ii) the skin hydrated with such carrier (wherein substantially all of the current passes between the electrodes through the skin) is in a range from about 10000:1 to about 1:100. In other words, the electric current distribution between Icarrier and Iskin is such that the value of Icarrier/Iskin is between about 10,000 and about 0.01. Icarrier is the portion of the total current going through the device (Itotal) that only passes through the carrier layer between the anode and cathode without traveling through the skin, whereas Iskin is the portion of Itotal that passes through the skin, namely, Itotal=Icarrier+Iskin. [0086] Decreasing the ratio of the conductance of the carrier to the conductance of the skin will result in a greater percentage of current passage through the skin, thereby enhancing iontophoretic delivery of any active agents being so delivered into the skin. Decreasing the conductivity of the carrier can nonexclusively be accomplished by adding less conductive materials to the carrier. Examples of such less conductive materials include, but are not limited to, oils such as silicone or hydrocarbon oils, air pockets such as air bubbles or air pockets in a semi-solid carrier, or polymer or clay beads. In one embodiment where the primary intention is to electrochemically generate species in the carrier, the value of Icarrier/Iskin is between about 10,000 and about 1. In another embodiment where the primary intention is to deliver electricity and/or active agents into the skin, the value of Icarrier/Iskin is between about 10 and about 0.01. Adjustment of the value of Icarrier/Iskin for a particular application can also be achieved by changing the distance between the first and the second electrode, or the distance between the two conductive electrode and the skin. For example, as the distance between the two conductive electrode decreases, the conductance measured between the two electrode increases and so is the Icarrier, leading to a increased value of Icarrier/Iskin. On the other hand, if the distance between the two conductive electrodes and the skin increases, the Iskin increases, leading to decreased value of Icarrier/Iskin. [0000] Electrochemically Generated Zinc Ions [0087] In one embodiment, zinc ions are electrochemically generated by a zinc anode in, or are subsequently added to, a topical composition. The topical composition is then applied to the barrier membrane of the user for the intended beneficial effects from the zinc ions and other active agents present in the topical composition. The active agents in the topical composition may contain anti-acne agents such as salicylic acid or benzoyl peroxide. One method of producing such electrochemically generated zinc ions is to incorporate an electrochemical device for zinc generation into a packaging and/or dispensing container of the topical composition (e.g., bottle equipped with a dispensing pump for an acne-treating/-preventing skin cream). In one embodiment, an electrochemical device including a zinc anode, a silver/silver chloride cathode, and a power source (e.g., a battery) electrically communicating with each other, is included within the dispensing pump. As the topical composition (such as a cream) passes out of the dispensing pump, it comes into contact with both the zinc anode and cathode and completes the electric circuit (i.e., an electric current runs from the anode into the cream, and returns to the power source via the cathode), the zinc anode begins to release zinc ions into the cream. Alternatively, the electrochemical device for zinc generation does not contain a battery. Instead, the zinc anode and cathode are connected to form a galvanic couple to generate zinc ions when both electrodes come into contact with the cream. [0000] Active Agents [0088] In one embodiment, the carrier contains one or more active agents. What is meant by an “active agent” is a compound (e.g., a synthetic compound or a compound isolated from a natural source) that has a cosmetic or therapeutic effect on the barrier membrane and the surrounding tissues (e.g., a material capable of exerting a biological effect on a human body) such as therapeutic drugs, including, but not limited to, organic and macromolecular compounds. Examples of such therapeutic drugs include peptides, polypeptides, proteins, and nucleic acid materials comprising DNA; and nutrients. Examples of polypeptide and protein active agents include thyrotropin-releasing hormone (TRH), vasopressin, gonadotropin-releasing hormone (GnRH or LHRH), melanotropin-stimulating hormone (MSH), calcitonin, growth hormone releasing factor (GRF), insulin, erythropoietin (EPO), interferon alpha, interferon beta, oxytocin, captopril, bradykinin, atriopeptin, cholecystokinin, endorphins, nerve growth factor, melanocyte inhibitor-I, gastrin antagonist, somatotatin, encephalins, melatonin, vaccines, botox (Botulinum neurotoxins), cyclosporin and its derivatives (e.g., biologically active fragments or analogs). Other active agents include anesthetics; analgesics (e.g., fentanyl and salts thereof such fentanyl citrate); drugs for treating psychiatric disorders, epilepsies, and migraine; drugs for stopping drug additions and abuses; anti-inflammatory agents; drugs to treat hypertension, cardiovascular diseases, gastric acidity and ulcers; drugs for hormone replacement therapies and contraceptives such as estrogens and androgens; antibiotics, antifungals, antiviral and other antimicrobial agents; antineoplastic agents, immunosuppressive agents and immunostimulants; and drugs acting on blood and the blood forming argans including hematopoietic agents and anticoagulants, thrombolytics, and antiplatelet drugs. Other active agents that can be delivered into the body using the shear device in the present invention include vaccines for various diseases, such as those for influenza, AIDS, hepatitis, measles, mumps, rubella, rabies, rubella, avercella, tetanus, hypogammaglobulinemia, Rh disease, diphtheria, botulism, snakebite, back widow bite and other insect bite/sting, idiopathic thrombocytopenic purpura (ITP), chronic lymphocytic leukemia, cytomegalovirus (CMV) infection, acute renal rejection, oral polio, tuberculosis, pertussis, Haemophilus b, Pneumococcus, and Staphylococcus aureus. [0089] In one embodiment, the carrier contains an anti-acne and/or anti-rosacea agent. Examples of anti-acne and anti-rosacea agents include, but are not limited to: retinoids such as tretinoin, isotretinoin, motretinide, adapalene, tazarotene, azelaic acid, and retinol; salicylic acid; benzoyl peroxide; resorcinol; sulfur; sulfacetamide; urea; antibiotics such as tetracycline, clindamycin, metronidazole, and erythromycin; anti-inflammatory agents such as corticosteroids (e.g., hydrocortisone), ibuprofen, naproxen, and hetprofen; and imidazoles such as ketoconazole and elubiol; and salts and prodrugs thereof. Other examples of anti-acne active agents include essential oils, alpha-bisabolol, dipotassium glycyrrhizinate, camphor, β-glucan, allantoin, feverfew, flavonoids such as soy isoflavones, saw palmetto, chelating agents such as EDTA, lipase inhibitors such as silver and copper ions, hydrolyzed vegetable proteins, inorganic ions of chloride, iodide, fluoride, and their nonionic derivatives chlorine, iodine, fluorine, and other valences, synthetic phospholipids and natural phospholipids such as Arlasilk™ phospholipids CDM, SV, EFA, PLN, and GLA (Uniqema, ICI Group of Companies, Wilton, UK). [0090] In one embodiment, the device of the present invention contains an anti-aging agent. Examples of suitable anti-aging agents include, but are not limited to: inorganic sunscreens such as titanium dioxide and zinc oxide; organic sunscreens such as octyl-methoxy cinnamates; retinoids; dimethylaminoathanol (DMAE), copper containing peptides, vitamins such as vitamin E, vitamin A, vitamin C, and vitamin B and vitamin salts or derivatives such as ascorbic acid di-glucoside and vitamin E acetate or palmitate; alpha hydroxy acids and their precursors such as glycolic acid, citric acid, lactic acid, malic acid, mandelic acid, ascorbic acid, alpha-hydroxybutyric acid, alpha-hydroxyisobutyric acid, alpha-hydroxyisocaproic acid, atrrolactic acid, alpha-hydroxyisovaleric acid, ethyl pyruvate, galacturonic acid, glucoheptonic acid, glucoheptono 1,4-lactone, gluconic acid, gluconolactone, glucuronic acid, glucuronolactone, isopropyl pyruvate, methylpyruvate, mucic acid, pyruvic acid, saccharic acid, saccaric acid 1,4-lactone, tartaric acid, and tartronic acid; beta hydroxy acids such as beta-hydroxybutyric acid, beta-phenyl-lactic acid, and beta-phenylpyruvic acid; zinc and zinc containing compounds such as zinc oxides; and botanical extracts such as green tea, soy, milk thistle, algae, aloe, angelica, bitter orange, coffee, goldthread, grapefruit, hoellen, honeysuckle, Job's tears, lithospermum, mulberry, peony, puerarua, nice, and safflower; and salts and prodrugs thereof. [0091] In one embodiment, the carrier contains a depigmentation agent. Examples of suitable depigmentation agents include, but are not limited to: soy extract; soy isoflavones; retinoids such as retinol; kojic acid; kojic dipalmitate; hydroquinone; arbutin; transexamic acid; vitamins such as niacin and vitamin C; azelaic acid; linolenic acid and linoleic acid; placertia; licorice; and extracts such as chamomile and green tea; and salts and prodrugs thereof. [0092] In one embodiment, the carrier contains a plant extract. Examples of plant extracts include, but are not limited to, feverfew, soy, glycine soja, oatmeal, what, aloe vera, cranberry, hazel witch, alnus, arnica, artemisia capillaris, asiasarum root, birch, calendula, chamomile, cnidium, comfrey, fennel, galla rhois, hawthorn, houttuynia, hypericum, jujube, kiwi, licorice, magnolia, olive, peppermint, philodendron, salvia, sasa albo-marginata, natural isoflavonoids, soy isoflavones, and natural essential oils. [0093] In one embodiment, the carrier contains metals such as metal ions, metal salts, metal complexes, fine metal powders, fine metal coated fibers and fabrics of synthetic or natural origin, or fine metal fibers. Examples of such metals include, but are not limited to, zinc, copper, aluminum, gold, silver, titanium. The metal ions provide benefits such as antimicrobial, anti-inflammatory, and/or sebum-reduction effects. The beneficial metal ions may be released from the metal anode as the result of an electrochemical oxidation reaction concurrent with electric current passage (e.g., zinc ions electrochemically generated from a zinc anode). [0094] In another embodiment, the beneficial ions may be generated indirectly from the electrochemical reactions at the electrode surface, such as the generation of hydrogen or hydroxyl ions at an inert electrode, which subsequently leads to a process to generate beneficial ions. For example, a device of the present invention may contain a power source, an inert anode (e.g., platinum, platinum coated conductive electrode, gold, or gold-coated conductive electrode), a reactive cathode (e.g., silver/silver chloride electrode), and an aqueous carrier composition containing an oxide (e.g., zinc oxide particles) among other active agents. During application to the skin, the electrolysis of water at the inert anode produces excess hydrogen ions which acidify the carrier toward a lower pH value, while the electrochemical reaction at the reactive cathode (e.g., the conversion of silver chloride to silver ions) does not affect the pH. As the solution becomes more acidic, the oxide starts to dissolve to release ions (e.g., zinc ions) for their beneficial effects to the barrier membrane. [0095] Other active agents include those commonly used as for topical treatment and in cosmetic treatment of skin tissues, such as topical antibiotics for wounds, topical antifungal drugs to treat fungal infections of the skin and nails, and antipsoriatic drugs to treat psoriatic lesions of the skin and psoriatic nails. [0096] Examples of antifungal drugs include but are not limited to miconazole, econazole, ketoconazole, sertaconazole, itraconazole, fluconazole, voricoriazole, clioquinol, bifoconazole, terconazole, butoconazole, tioconazole, oxiconazole, sulconazole, saperconazole, clotrimazole, undecylenic acid, haloprogin, butenafine, tolnaftate, nystatin, ciclopirox olamine, terbinafine, amorolfine, naftifine, elubiol, griseofulvin, and their pharmaceutically acceptable salts and prodrugs. In one embodiment, the antifungal drugs are an azole, an allylamine, or a mixture thereof. [0097] Examples of antibiotics (or antiseptics) include but are not limited to mupirocin, neomycin sulfate bacitracin, polymyxin B, 1-ofloxacin, tetracyclines (chlortetracycline hydrochloride, oxytetracycline-10 hydrochloride and tetrachcycline hydrochoride), clindamycin phsphate, gentamicin sulfate, metronidazole, hexylresorcinol, methylbenzethonium chloride, phenol, quaternary ammonium compounds, tea tree oil, and their pharmaceutically acceptable salts and prodrugs. [0098] Examples of antimicrobials include but are not limited to salts of chlorhexidine, such as lodopropynyl butylcarbamate, diazolidinyl urea, chlorhexidene digluconate, chlorhexidene acetate, chlorhexidene isethionate, and chlorhexidene hydrochloride. Other cationic antimicrobials may also be used, such as benzalkonium chloride, benzethonium chloride, triclocarbon, polyhexamethylene biguanide, cetylpyridium chloride, methyl and benzothonium chloride. Other antimicrobials include, but are not limited to: halogenated phenolic compounds, such as 2,4,4′,-trichloro-2-hydroxy diphenyl ether (Triclosan); parachlorometa xylenol (PCMX); and short chain alcohols, such as ethanol, propanol, and the like. In one embodiment, the alcohol is preferably at a low concentration (e.g., less than about 10% by weight of the carrier, such as less than 5% by weight of the carrier) so that it does not cause undue drying of the barrier membrane. [0099] Examples of antipsoriatic drugs or drugs for seborrheic dermatitis treatment include, but are not limited to, corticosteroids (e.g., betamethasone dipropionate, betamethasone valerate, clobetasol propionate, diflorasone diacetate, halobetasol propionate, triamcinonide, dexamethasone, fluocinonide, fluocinolone acetonide, halcinonide, triamcinolone acetate, hydrocortisone, hydrocortisone verlerate, hydrocortisone butyrate, aclometasone dipropionte, flurandrenolide, mometasone furoate, methylprednisolone acetate), methotrexate, cyclosporine, calcipotriene, anthraline, shale oil and derivatives thereof, elubiol, ketoconazole, coal tar, salicylic acid, zinc pyrithione, selenium sulfide, hydrocortisone, sulfur, menthol, and pramoxine hydrochloride, and salts and prodrugs thereof. [0100] Examples of anti-viral agents for viral infections such as herpes and hepatitis, include, but are not limited to, imiquimod and its derivatives, podofilox, podophyllin, interferon alpha, acyclovir, famcyclovir, valcyclovir, reticulos and cidofovir, and salts and prodrugs thereof. [0101] Examples of anti-inflammatory agent, include, but are not limited to, suitable steroidal anti-inflammatory agents such as corticosteroids such as hydrocortisone, hydroxyltriamcinolone alphamethyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fluadrenolone, fluclarolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butylester, fluocortolone, fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenalone acetonide, medrysone, amciafel, amcinafide, betamethasone, chlorprednisone, chlorprednisone acetate, clocortelone, clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylproprionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, betamethasone dipropionate, triamcinolone, and salts are prodrugs thereof. The preferred steroidal anti-inflammatory for use in the present invention is hydrocortisone. A second class of anti-inflammatory agents which is useful in the compositions of the present invention includes the nonsteroidal anti-inflammatory agents. [0102] Other active agents include, but are not limited to, wound healing enhancing agent, such as recombinant human platelet-derived growth factor (PDGF) and other growth factors, ketanserin, iloprost, prostaglandin E1 and hyaluronic acid, scar reducing agents such as mannose-6-phosphate, analgesic agents, anesthetics, hair growth enhancing agents such as minoxadil, hair growth retarding agents such as eflornithine hydrochloride, antihypertensives, drugs to treat coronary artery diseases, anticancer agents, endocrine and metabolic medication, neurologic medications, medication for cessation of chemical additions, motion sickness, protein and peptide drugs. [0103] In one embodiment, the carrier contains a fragrance effective for reducing stress, calming, and/or affecting sleep such as lavender and chamomile. [0104] The amount of the active agent in the carrier will depend on the active agent and/or the intended use of the device. In one embodiment, the carrier contains a safe and effective amount of the active agent, for example, from about 0.001 percent to about 20 percent, by weight such as from about 0.01 percent to about 5 percent, by weight, of the carrier. [0000] Light Emitting Diode [0105] In one embodiment, the device contains one or more light emitting diodes. Light emitting diodes (LEDs) of certain spectrum may be incorporated into the device to emit light to the barrier membrane (e.g., to treat skin conditions such as acne and rosacea). The light emitting diode may also provide a signal to the user indicating that the device is operating properly. [0106] In one embodiment, the LED is one that emits light periodically (i.e., a blinking LED). In a further embodiment, such LED also modulates the current passing through the barrier membrane to form a pulsatile DC current. Such pulsatile DC current can enhance delivery of active agents into the barrier membrane, stimulate biological responses in the barrier membrane such as enhancing wound healing (e.g., in acne lesions), and/or enhanced skin sensation which serves a signal to a user that the device is working. Another potential advantage of using a blinking LED is to produce pulsatile DC current without the need of a complex electric circuit. [0107] The spectrum of the LED's according to the current invention may range from about 300 nm to about 1500 nm, such as from about 350 nm to about 1000 nm. In one embodiment, the range of the LED includes violet-blue, green, red, and infrared ranges, e.g., from about 400 nm to about 450 nm such as from about 407 nm to about 420 nm; from about 510 nm to about 550 nm; from about 600 nm to about 700 nm; and from about 1300 nm to about 1500 nm. In one embodiment, the device contains two LEDs, one that emits light having a wavelength of from about 400 nm to about 500 nm and one which emits light from about 700 nm to about 1000 nm. Photosensitizer agents, such as 5-aminolaevulinic acid (ALA), hypericin, St. John's wort powder or extract, or other synthetic or natural photosensitizer agents, may be incorporated into the carrier as active agents to be delivered and irradiated by the device with LED's of the present invention. The light irradiation from the LED's, together with the photosensitizer agent(s) and other aforementioned active agents, electrochemically generated oxidizing agents (e.g., peroxides, nascent oxygen, chlorine dioxide, and chlorine), and/or electric stimulation of the barrier membrane may work synergistically to achieve an improved efficacy in treating membrane disorders such as acne and rosacea. [0000] General Use [0108] In one embodiment, the device is used for the treatment of a barrier membrane condition (e.g., the delivery of an active agent light, and/or electricity into the membrane such as the skin, eye (cornea, retina, etc.), oral, buccal, nasal, vaginal, gastrointestinal, or rectal mucosa barrier membrane, of a human). In one embodiment, the device is used for the treatment of skin conditions. Examples of such treatments include, but are not limited to: treatment of acne, rosacea, or other microbial infections of the skin; reduction the visible signs of skin aging (e.g., wrinkles, sagging, and age-spots); folliculitis and pseudo-folliculitis barbae; treatment of wounds and lesions (e.g., enhancing healing and scar reduction); sebum regulations (e.g., sebum reduction or oily/shining skin appearance inhibition or control); pigmentation regulation (e.g., reduction of hyperpigmentation or pigmentation of light skin); hair growth retardation (e.g., skin on the leg) or hair stimulation (e.g., scalp); and treatment of dermatitis (e.g., atopic, contact, or seborrheic dermatitis) and/or psoriasis. [0109] In another embodiment, the device is used for the treatment of mucosal conditions (e.g., mucosa in the oral or vaginal cavities). Examples of such treatments include, but are not limited to: treatment of vaginal candidiasis and vaginosis, genital and oral herpes, cold sore, canker sore, oral hygiene, periodontal disease, and other microbial infections of the mucosa. [0110] Another embodiment of the present invention is the device induces certain desirable biological responses that facilitate the treatment of the barrier membrane conditions. These desirable biological responses may be induced by the electric current passage through the barrier membrane, and/or the electrochemically generated oxidizing materials, together with the active agents delivered by iontophoresis from the carrier, in treating the barrier conditions. Examples of the desirable responses of the barrier membrane may include, but are not limited to, sebum regulation (e.g., reduction of sebaceous gland activity), inhibition of anaerobotic microbial growth and establishment of a healthier membrane microflora or (e.g, reduction of P. acne growth and of production of irritating fatty acids), blood vasoconstriction (thus promoting local accumulation of active agents or removal of dark circle under the eye due to deoxyhemoglobins), enhanced tissue immunological activity (e.g, increased elimination of pathogenic microbes on tissue's own defense systems), improved tissue repairing (e.g., enhanced healing and reduced scarring of lesions such as acne lesions), and improved keratolytic activity of the carrier (e.g., softening of keratin plugs of comedos in whiteheads and blackheads of acne, and facilitating their removal). [0111] In another aspect, the invention also features the method of converting an active agent from a less active form to a more active form via oxidation or reduction via an inert electrode (e.g., cystine to cysteine, disulfide acetyl-cysteine to acetyl-cysteine, and retinol to retinoic acid). Thus, an unstable agent can be stored in a more stable form and converted to its active form prior to administration. In a further aspect, the generation of reducing agents by the device of the present invention can be used to stabilize oxygen-labile active agents. Examples of such oxygen-labile active agents include, but are not limited to, retinoids, ascorbic acid, and benzoyl peroxide. [0112] In one embodiment, the invention also features the method of converting an active agent from a less active form to a more active form via oxidation at an reactive anode, such as an anode made of zinc, magnesium, copper, aluminum, alloy or mixture of these metals. For example, an anode made of zinc releases zinc ions with the passage of an electric current through the electrode. The zinc ions generated by such an electrochemical reactions are then subsequently delivered by the electric repulsion of the positively charged anode into the barrier membrane. In one embodiment, such ions are deposited into the hair follicles and/or sebaceous glands to inhibit P. acnes growth and/or suppress skin tissue inflammation resulted from P. acnes over growth before the treatment. Similarly, a zinc-copper alloy anode or another zinc-beneficial metal alloy releases both zinc ions and copper ions or the other beneficial ions, respecytively, into the hair follicles and sebaceous glands for acne treatment and prevention. [0000] Skin Conditions [0113] In one embodiment, the device of the present invention is used to treat skin conditions such as: acne and acne (e.g., blackheads and whiteheads) and acne-related skin conditions such as rosacea and nodule-cystic; hyperpigmentation such as freckles, melasma, actinic and senile lentigines, age-spots, post-inflammatory hypermelanosis, Becker's naevus, dark circles under the eye, and facial melanosis; stretch marks; and skin aging effects on the skin (such as those caused by photodamage) including wrinkling, roughness, pigmentary alterations, sallowness, fine lines, and laxity, by delivering active agents that including pre-formulated active agents in the carrier and electrochemically generated active agents (e.g., beneficial metal ions) by the electrodes, and/or by providing electric stimulation to the skin tissues. [0114] In one embodiment, the device of the present invention provide multiple mechanism of actions to treat such conditions: namely, (a) target-delivering pre-formulated active agents into the pilosebaceous unit by iontophoresis and electro-osmosis; (b) electrochemically generating new active agents (e.g., the beneficial metal ions from a reactive anode) and targeted delivery of the freshly generated active agents to the pilosebaceous unit (e.g., beneficial ions such as zinc and copper have known to enhance skin's own immune system); and/or (c) providing electric stimulation to the pilosebaceous unit and its surrounding skin tissues to increase blood circulation, and to treat the skin by reducing inflammation, enhancing wound healing, and/or increasing skin exfoliation. [0000] Wounds and Scars [0115] In one embodiment, the device of the present invention can be incorporated into wound dressings and bandages to provide electric therapy for healing enhancement and scar prenvetion. In one embodiment, the wound exudation fluid and/or wound cleansing solution serves to activate a galvanic wound dressing/bandage to deliver active agents pre-incorporated in the wound dressing/bandage and/or to generate electrochemically beneficial metal ions followed with delivery of the beneficial metal ions into the wound. The device also treats the wound with therapeutic electric current which may increase blood circulation, stimulate tissue immune response, and/or suppress tissue inflammation, which may lead to accelerated healing and reduced scarring. [0000] Enhanced Chemical Peel [0116] Chemical peel treatments are an in-office procedure that involves the application of a chemical agent to the skin to induce controlled destruction or exfoliation of old skin and stimulation of new epidermal growth with more evenly distributed melanin. When peel agents reach the dermal layer, important wound-healing activities occur that cause skin remodeling and skin smoothing, both are anti-aging benefits. Delivery of chemical peel agents contained with the carrier of electrical generating device/composition could be used in the treatments for a variety of skin disorders, including but not limiting to, acne, post-inflammatory hyperpigmentation, melasma, scar, photo-damage, age-spot, wrinkle, stretch mark, birth mark, uneven texture and tone, warts, and pseudofolliculitis barbae. The device/composition may also have the additional advantage of reducing skin irritation and decreasing the risk of precancerous and early cancerous lesions of the photo-aged skin on the face, because the iontophoretically administrated chemical peel may enable the use of a much lower concentration of chemical peeling agents in comparison to the standard chemical peel approach without the use of such device. Reduction of required chemical peeling agents may also minimize risk of prolonged post-peel erythema, inflammation and scars from chemical peel while achieving desirable benefits. [0117] Examples of chemical peel agents include, but are not limited to: hydoxy acids such as α-hydroxy acids such as lactic acid, malic acid, glycolic acid, arginine glycolate, ammonium glycolate and sodium glycolate; β-hydroxy acids such as salicylic acid; polyhydroxy acids (PHA) such as gluconolactone; and non-hydroxy acids such as acetic acid, trichloroacetic acid (TCA), pyruvic acid an alpha-keto-acid, phenol, their derivatives or their combinations. They can also be combined with sulfur, resorcinol, retinoids or other active actives such as Jessner solution peel (which contains lactic acid, salicylic acid, resorcinol and ethyl alcohol). Chemical peeling agents of the present invention may also include, but are not limited, protease agents or their derivatives such as acid protease in the apoenzyme, holoenzyme, idoenzyme, or zymogen form. Examples include pepsin, Bromelain, papaya, and cathepsin. Further examples include natural extract chemical peeling agents such as fruit extracts, mushroom extract, and other plant extracts. [0118] In one embodiment, the duration of the application of the device to the skin is from about 2 to about 10 minutes depending on the individual skin conditions. In one embodiment, the carrier contains from about 0.1% to about 70% by weight of such chemical peel agent, such as from about 0.5% to about 20% such as from about 2% to about 10%. [0000] Shape [0119] The device includes a housing that may be fabricated into various shapes and sizes to fit the contours of various anatomical surfaces of the barrier membranes. For examples, the housing may be a substrate made in the shape of a whole facial mask with openings/holes to expose the eyes, eye bows, nose, and mouth; a partial facial mask covering only the upper or lower half of the face; or a patch covering only the forehead, or the under eye region, the chin and jaw region, the neck, the back, wound, acne lesion or pimple, or other specific area of a barrier membrane in need of treatment. [0120] In one embodiment of the present invention, the housing is a water-insoluble substrate containing a galvanic couple, for example, a fine zinc wire or a fine zinc-coated fiber (e.g., zinc-coated polymer fiber) connected to a fine copper wire or a fine copper-coated fiber (e.g., copper-coated polymer fiber). One or more such fine galvanic couple wire(s) or fiber(s) may be incorporated into the substrate to create a device which, when in contact with the carrier (such as tap water or a liquid or semi-liquid composition including active agents) generates an electric current. In one embodiment, a galvanic couple-containing substrate may be made of multiple layer, for example, a layer of the zinc-containing substrate (e.g., a fine zinc wire- or a fine zinc-coated fiber in a woven or non-woven fabric) over a layer of copper-containing substrate (e.g., a fine copper wire- or a fine copper-coated fiber in a woven or non-woven fabric). During use, the layers contact each other to form the galvanic couple. In a further embodiment, the device releases beneficial ions (e.g., zinc ions or aluminum ions) that are delivered to the barrier membrane (e.g., the skin) when such a substrate is applied by the user (e.g., used as a wipe for cleaning the skin or a facial patch or mask to treat the skin). Active agents may also be incorporated into the substrate during manufacturing processes or be subsequently applied to the substarte prior to the application to the barrier membrane (e.g., in the form of an electrolyte or active agent containing liquid spray to wet the substrate). In one embodiment, the fabric is used as a dry wipe or a dry full or partial facial mask, to be wetted immediately before use, by applying water to the dry wipe or facial mask to pre-moisturized skin (e.g., by washing with tap water). [0121] By “water insoluble” is meant that the substrate, upon immersion in distilled water at 25° C., does not readily dissolve in or readily break apart. The water-insoluble substrate may, however, be disintegrated and/or dissolved slowly, i.e., over a period of several hours up to several days. A wide variety of materials can be used as the water-insoluble substrate. Examples of suitable substrates include, but are not limited to, non-woven substrates, woven substrates, hydro-entangled substrates, air entangled substrates, natural sponges, synthetic sponges, and polymeric netted meshes. [0122] The water insoluble substrates may be flushable. As used herein, by “flushable” is meant that the substrate will pass through at least 10 feet of waste pipe in two toilet flushes. The material may also be biodegradable. [0123] In one embodiment, the substrates contain a non-woven material. By “non-woven” is meant that the substrate, or a layer of the substrate, is comprised of fibers that are not woven into a fabric but rather are formed into a sheet, mat, or pad layer. The fibers can either be random (i.e., randomly aligned) or they can be carded (i.e., combed to be oriented in primarily one direction. Furthermore, the non-woven substrate can be composed of a combination of layers of random and carded fibers). [0124] Non-woven substrates may be comprised of a variety of natural and/or synthetic materials. By “natural” is meant that the materials are derived from plants, animals, insects, or byproducts of plants, animals, and insects. By “synthetic” is meant that the materials are obtained primarily from various man-made materials or from natural materials, which have been further altered. Non-limiting examples of natural materials useful in the present invention are silk fibers, keratin fibers (such as wool fibers, camel hair fibers) and cellulosic fibers (such as wood pulp fibers, cotton fibers, hemp fibers, jute fibers, and flax fibers). [0125] Examples of synthetic materials include, but are not limited to, those selected from the group containing acetate fibers, acrylic fibers, cellulose ester fibers, cotton fibers, modacrylic fibers, polyamide fibers, polyester fibers, polyolefin fibers, polyvinyl alcohol fibers, rayon fibers, polyurethane foam, and mixtures thereof. [0126] Substrates made from one ore more of the natural and synthetic materials useful in the present invention can be obtained from a wide variety of commercial sources such as Freudenberg & Co. (Durham, N.C. USA), BBA Nonwovens (Nashville, Tenn. USA), PGI Nonwovens (North Charleston, S.C. USA), Buckeye Technologies/Walkisoft (Memphis, Term. USA), and Fort James Corporation(Deerfield, Ill. USA). [0127] Methods of making non-woven substrates are also well known in the art. Such methods include, but are not limited to, air-laying, water-laying, melt-blowing, spin-bonding, or carding processes. The resulting substrate, regardless of its method of production or composition, is then subjected to at least one of several types of bonding operations to anchor the individual fibers together to form a self-sustaining web. The non-woven substrate can be prepared by a variety of processes including hydro-entanglement, thermally bonding, and combinations of these processes. Moreover, the substrates can have a single layer or multiple layers. In addition, a multi-layered substrate can include film layer(s) (e.g., aperture or non-aperture film layers) and other non-fibrous materials. [0128] Strength or firmness of the non-woven material may be a desirable attribute. This can be achieved, for example, by the addition of binding materials, such as wet strength resins, or the material may be made of polymer binder coatings, stable fibres, e.g. based on cotton, wool, linen and the like. Examples of wet strength resins include, but are not limited to, vinyl acetate-ethylene (VAE) and ethylene-vinyl chloride (EVCL) Airflex emulsions (Air Products, Lehigh, Pa.), Flexbond acrylic polymers (Air Products, Lehigh, Pa.), Rhoplex ST-954 acrylic binder (Rohm and Haas, Philadelphia, Pa.), and Ethylene-vinyl acetate (EVA) emulsion (DUR-O-SET® by National Starch Chemicals, Bridgewater, N.J.). The amount of binding material in the substrate may range from about 5% to about 20%, by weight, of the substrate. [0129] Non-woven materials of increased strength can also be obtained by using the so-called spunlace or hydro-entanglement technique. In this technique, the individual fibers are twisted together so that an acceptable strength or firmness is obtained without the need to use binding materials. The advantage of the latter technique is the excellent softness of the non-woven material. [0130] In one embodiment, the non-woven material is made of a superabsorbent polymer. For the purposes of the present invention, the term “superabsorbent polymer” refers to materials which are capable of absorbing and retaining at least about 10 times their weight in body fluids under a 0.5 psi pressure. The superabsorbent polymer particles of the invention may be inorganic or organic crosslinked hydrophilic polymers, such as polyvinyl alcohols, polyethylene oxides, crosslinked starches, guar gum, xanthan gum, and other material known to the art of absorbent article manufacture. [0131] Additives may also be added in order to increase the softness of the substrates. Examples of such additives include, but are not limited to, polyols such as glycerol, propylene glycol and polyethylene glycol, phthalate derivatives, citric esters, surfactants such as polyoxyethylene (20) sorbitan esters, and acetylated monoglycerides. [0132] Sensory attributes may also be incorporated to the insoluble non-woven substrates. Examples of such sensory attributes include, but are not limited to color, texture, pattern, and embossing. [0133] In one embodiment, the device of the present invention is for use as a wipe or towel (for example, having a surface area of from about 20 cm2 to about 10,000 cm2). In another embodiment, the device of the present invention is for use as a therapeutic patch or mask for application to a portion of or substantially all of the face (for example, having a surface area of from about 1 cm2 to about 600 cm2). [0134] In one embodiment, the carrier is present in at least about 50%, such as at least about 75%, by weight of the total weight of the water insoluble substrate prior to use. In another embodiment, (i) the liquid carrier is present in less than about 10%, such as less than about 1%, by weight of the total weight of the water insoluble substrate (for example, the device may not contain any carrier prior to use). In a further embodiment, the product contains instructions for the user to either (i) wet the substrate prior to application or (ii) wet the barrier membrane (e.g., the skin) with water and/or another liquid prior to application. [0000] Devices [0135] One embodiment of the present invention is represented schematically in FIG. 1. The device 500 contains a removable release liner 100, a carrier layer 120, a first conductive electrode 140, a second conductive electrode 240, electric lead wires 110 and 210 connecting the two ends of an electrically insulated connecting wire 350 to the two dissimilar conductive electrodes, an optional electric power switch 330 located on the lead wire 210, a backing layer 160, and a cover layer 340. [0136] The gap “b” depicts the distance between two conductive electrodes 140 and 240 to the release liner (or the membrane following application of the device), and the gap “a” represents the distance between two oppositely charged conductive electrodes. In one embodiment, gap “a” is between 0 to about 20 centimeter, and gap “b” is between 0 and to about 1 centimeters. In another embodiment, the ratio of gap “a” to gap “b” is at least about 0.1, such as at least about 5. In one embodiment that ratio is from about 0 to about 20, such as from about 0.1 to about 5. [0137] In devices that contain a battery as a power source, electrically insulated connecting wire 350 can be replaced with a battery (not shown) in the Figures. The battery may be encased in an electric insulating, water-impermeable polymer layer (not shown in the Figures). Optionally, there can be an electric circuit (not shown) in device 500 to provide a constant current located between the battery (not shown) and conductive electrode 140 and/or conductive electrode 240. [0138] When a zinc air battery is used as the power source of the device 500, the battery (not shown) is constructed in such a way that the orifice on the stainless steel cover is facing the opposite side of the carrier layer 120. An orifice is made on the battery cover layer to expose the orifice on the zinc air battery that is covered by a removable oxygen-impermeable cover. In this case, the power switch 330 is replaced by the removable oxygen-impermeable cover. The removable oxygen-impermeable cover can be used to begin (by removing it) or to halt the electrotransport process of the device (by re-covering the orifice). [0139] The backing layer 160 may be impermeable to the active agent contained within the carrier layer 120, and is preferably not permeable to water or other solvents in the carrier layer 120. The backing layer 160 and cover layer 340 may be made of flexible material that is impermeable to water and electrically insulating, e.g., polymers such as polyethylene, polypropylene, polyvinyl acetate, polyurethane, silicone rubber, or polyvinyl chloride. [0140] In a further embodiment, the backing layer 160 is permeable to electrochemically generated gases (e.g., oxygen, chlorine, and hydrogen) in order to limit excess accumulation of the gases in the carrier which can cause tissue irritation and/or undesirable deformation of the device. Examples of such “breathable backing” material include, but are not limited to, a cotton or synthetic woven and nonwoven fabric layer, such as those fabric materials commonly used for bandages and sports bandages. [0141] The carrier layer 120 is an adhesive hydrogel containing the active agent. The active agent may be incorporated into the carrier layer 120 as dissolved molecules and ions, dispersed solid particles, or liquid droplets such as cream, lotion, emulsion, multi-emulsion, microemulsion, and/or liposome compositions. The carrier layer 120 may also contain a solid supporting matrix (e.g., a gauze, non-woven or sponge-like material). [0142] A removable liner sheet 100 covers the carrier layer 120. The selection of the removable release-liner 100 is dependent on the type of the adhesive hydrogel used in carrier layer 120. The release liner sheet 100 is typically a polymer sheet or a paper or fabric coated with a polymer, which has weak adhesion toward the adhesive hydrogel layer 120, thereby allowing it to be easily removed from the carrier layer 120 prior to use without damaging the carrier layer 120. Examples of the polymers typically used for the release liner 100 are silicones and polyethylenes. Alternatively, a wax may be used in the place of the polymer to coat the release liner 100. [0143] In addition to, or in lieu of, the use of an adhesive in the carrier layer 120, the device 500 may be fastened to the barrier membrane with an adhesive tape, an elastic band, a band with a buckle (similar to a leather watch band), or a Velcro® band. [0144] In order to use device 500, the removable release liner sheet 100 is peeled off, and the carrier hydrogel layer 120 of the device 500 is affixed to a barrier membrane, such as the skin or mucosal membranes such as vaginal, oral, buccal, nasal, gastrointestinal or rectal mucosa barrier membrane, of the user. The device may be directly affixed to the barrier membrane if the carrier layer 120 contains an adhesive hydrogel. An electric potential is applied across the conductive electrodes 140 and 240 by switching on the power switch 330. [0145] Another embodiment of the present invention is represented schematically in FIG. 2. The electrically insulated connecting wire 350 is located within the carrier layer 120. The advantage of this arrangement includes reduced bulkiness, enhanced esthetics and user comfort. [0146] The lighting portion of the LED 122 is preferable located in the carrier layer 120 in close proximity to the skin. Locating the light source in the carrier layer 120 affixed to the barrier membrane has an advantage of minimizing the loss of light energy from reflection of skin surface. In addition, a light reflective layer may be used as the backing layer 160 (e.g., metalized polymer film) to further enhance the efficacy of phototherapy, and to achieve more homogeneous irradiation. The backing layer 160 may optionally be perforated as certain spots to make the light visible to the user to serve as an indicator that the device is working normally. [0147] Another embodiment of the present invention is represented schematically in FIG. 3. Backing layer 160 (e.g., the housing) contains an adhesive layer 130 coated onto the outer rim of the backing layer 160 for affixing device 500 to membrane during application. The adhesive in the adhesive layer 130 may be a polymeric, pressure sensitive and/or nonconductive. Suitable adhesive materials include, but are not limited to, silicones, polyisobutylenes and derivatives thereof, acrylics, natural rubbers, and combinations thereof. Suitable silicone adhesives include, but are not limited to, Dow Corning 355 (available from Dow Corning of Midland, Mich.); Dow Corning X7-2920; Dow Corning 0 X7-2960; GE 6574 (available from General Electric Company of Waterford, N.Y.); and silicone pressure sensitive adhesives. Suitable acrylic adhesives include, but are not limited to, vinyl acetate-acrylate multipolymers, including, such as Gelva-7371 (available from Monsanto Company of St. Louis, Mo.); Gelva T 7881; Gelvac 2943; 1-780 medical grade adhesive available from Avery Dennison of Painesville, Ohio; and acrylic pressure sensitive adhesives. [0148] One embodiment of the present invention is a dual-pack system, in which the device and the carrier (or a portion of the carrier) are packaged separately. One portion of the carrier layer 120 may be an anhydrous liquid-immobilizing matrix, such as a dry woven or nonwoven fabric, a sponge, or a dehydrated hydrogel layer (e.g., freez-dried hydrogel), while the liquid portion of the carrier, such as a solution, gel, or cream containing active agents, is packaged in a separate liquid containing compartment (not shown in the Figures), such as a unit dose pouch, a breakable container or a bottle. Prior to use, the liquid-containing compartment is broken and the liquid or semisolid portion of the carrier is applied to the liquid-immobilizing matrix to activate the current generation for skin application. The active agents are either incorporated into the liquid-immobilizing matrix or the liquid/semisolid composition. [0149] One embodiment of the present invention is represented schematically in FIG. 4. The conductive electrodes 140 and 240 is in electric communication with each other through direct connection, namely, the gap “a” (the distance between two oppositely charged conductive electrodes) is equal to zero. Two conductive electrodes forms a galvanic couple which is contact the carrier layer 120 enclosed in backing layer 160 with an opening affixed to the release liner 100 with an adhesive layer 130. One major advantage of this configuration is its simplicity and easiness to manufacture. [0150] Another embodiment of the present invention is represented schematically in FIG. 5. The electrotransport device 800 containes two electrode assemblies 200 and 600, respective adhesive layers 230 and 630, respective carrier layers 220 and 620, respective conductive electrodes 240 and 640, respective backing layers 270 and 670, respective electric leads 210 and 610, electrically insulated connecting wire 350 and optional electric switch 330. Similar to the aforementioned typical iontophoresis device, the two electrode assemblies 200 and 600 are to be affixed to the barrier membrane apart from each other, after the release liner 100 is removed prior to use. [0151] In one embodiment, the carrier layer 120 contains at least two active agents carrying opposite electric charges. One example of such a composition is a composition containing from about 0.5 to about 2% of salicylic acid and from about 0.01 to about 0.2% of a cationic quaternary ammonium antimicrobial agents (such as benzalkonium chloride, benzethonium chloride, methyl benzethonium chloride, and cetylpyridinium chloride), phenol, and/or chlorhexidine gluconate. The device 500 of the present invention can simultaneously deliver both active agents of opposite charges into the membrane. [0152] FIGS. 6 and 7 show two examples of different configurations of dissimilar conductive electrodes 140 (shown by a double line) and 240 (shown by a single line) in carrier layer 120, connected by electrically insulated wires 350 (shown by a triple line) to form a galvanic couple power source. FIG. 6 shows that the conductive electrodes 140 and 240 are arranged in an inter-digitated configuration. FIG. 7 shows the conductive electrodes in a concentric configuration. [0153] FIGS. 8 and 9 show two examples of other configurations of dissimilar conductive electrodes 140 and 240 in carrier layer 120, connected to each other either connective wire 350 as in FIG. 8 or by a direct physical contact at each intersection 370 as in FIG. 9 to form a plural of galvanic couple power sources, which are in contact with the carrier layer 120. The conductive electrodes 140 and 240 in FIGS. 8 and 9 are arranged in parallel and perpendicular configurations, respectively. [0154] The alternating-parallel arrangement of the conductive electrodes 140 and 240 in FIG. 8 provides a more uniform electric current distribution throughout the carrier layer 120 and the underlying skin tissue, and consequently, assist in enabling a more uniform delivery of active agents into the skin. One exemplifying fabrication method for the galvanic device shown in FIG. 8 is by weaving a silver-coated polymer fabric and zinc-coated polymer fabric (or zinc wire) into a liquid-absorbant fabric layer according to the parallel electrode pattern, then connecting zinc and silver electrodes by printing over the silver and zinc regions with an electric conductive ink (e.g., conductive silver or carbon ink). Covering another layer of an electric insulating ink over the electric conductive ink will produce the electrically insulated connecting wire 350. [0155] Another fabrication method for the device of FIG. 8 is via printing: to print onto a non-conductive polymeric substrate layer (e.g., the polymer material made of the backing layer 160) using a conductive silver or silver-silver chloride ink to produce the first conductive electrode; and to print the second conductive electrode using a conductive zinc ink. The two dissimilar conductive electrodes are then connected by printing cross them with either the conductive silver or zinc ink (or a different conductive ink such as carbon ink). A covering ink may then optionally be printed over the connecting wire to produce an electric insulating polymer layer over it. If the device is made without insulating with an electrically insulating coverying layer, the resulting device is a variation of that depicted in FIG. 9. [0156] FIG. 9 is a top view of one embodiment in accordance with the invention showing the conductive electrodes 140 and 240 connected to each other by direct physical contact at the intersections 370 to form a galvanic couple power source, which is in contact with the carrier layer 120. The conductive electrodes 140 and 240 are arranged in a perpendicular configuration. The aforementioned fabrication methods for the device in FIG. 8 is also suitable to produce this device. [0157] FIG. 10 is a top view of one embodiment in accordance with the invention showing a device made of a zinc mesh having conductive electrodes 140 (shown in bold lines) and electrodes 240 (shown in double lines) connected by electrically insulated connecting wires 350 (shown in single lines) embedded in the carrier layer 120. The conductive electrodes 140 are uncoated regions of the zinc mesh. The conductive electrodes 240 is prepared by coating the designated portion of the zinc mesh with a silver-silver chloride ink. The electrically insulated connecting wire 350 is prepared by coating the designated portion of the zinc mesh with an electrically insulating paint, ink, or polymer solution. [0158] FIG. 11 is a top view of one embodiment in accordance with the invention showing the conductive electrodes 140 and 240 embedded in the carrier layer 120. The conductive electrodes 140 are made of a piece of zinc mesh. The conductive electrodes 240 are prepared by coating the designated portion of the zinc mesh with a silver-silver chloride or silver ink, or by other silver depositing methods such as electroless deposition (chemical reduction deposition), electroplating, plasma spray, or vacuum deposition. Elimination of the electrically insulated connecting wire 350 in this design would simplify the manufacturing process. The location, pattern, shape, and size of the electrode of metallic silver, silver-silver chloride or silver-silver oxide may vary depending on the need of a particular products. [0159] Zinc mesh (or “expanded zinc” as common called in battery and anti-corrosion fields) may be prepared from a thin zinc foil with mechanical perforation and subsequent expansion into net-like patterns. The major advantages of a zinc mesh anode in the galvanic device of the present invention are its ability of forming and retaining the desirable mask/patch shape by a user, stretching by a user toward any directions to form mask/patch of desirable size; and being breathable. [0160] It should be noted although the use of zinc mesh is described here as an example of electrode designs, other aforementioned materials suitable for galvanic couple formation and for conductive electrodes can also be made into a mesh or an expanded form to provide the same function. [0161] Zinc mesh also has the ability to conform to the shape of the membrane surface (e.g., the shape of an individual's face) by gently pressuring it, and to retain this shape. This capability makes it uniquely suitable for a facial mask or certain skin patches to better fit the contours of certain anatomic features of the face (e.g., a nose patch) or body areas. This unique feature also assists in better electric contact and may also reduce dependence on using adhesives to affix the device to the skin. [0162] It is also highly convenient and desirable to a consumer if a facial mask or patch can be stretched to different sizes in order to cover a particular skin area without compromising its electric performance. A zinc mesh anode (or other mesh conductive electrode) is uniquely capable to fulfill this consumer need. In another embodiment, the mesh is not expanded before use so that the device is smaller and more compact for easy storage and carrying. Rather, it is stretched open to a desired size during application by a consumer. [0163] Good breathability is important for a facial mask or a patch of relatively large size, especially if the device is designed to be worn by a user for an extended period of time (e.g., longer than one half hour such as overnight). In order to make aforementioned device stretchable and/or breathable, the carrier layer 120 and backing layer 160 should also be stretchable and breathable, such as stretchable woven and nonwoven fabric materials. [0164] In another embodiment, the backing layer 160 in FIGS. 3-5, can be perforated or eliminated entirely for a mask or patch device, which is especially suitable for the application of short duration, e.g., from about 5 to about 30 minutes. As water in the carrier composition evaporates, the electric conductance and the electric current decrease. Eventually, the electric current will significantly diminish, providing in essence a self-terminating device to serve as a safety measure for the user to prevent any unintentional over-exposure of the skin to the electric current and potential resulting skin damage. [0165] One example of such a self-terminating device is a galvanic cloth facial mask made with a zinc mesh partially coated with silver-silver chloride ink, which is placed in between a backing film/housing (e.g., a perforated or nonperforated polyethylene film) and a nonwoven fabric (e.g., a polyester and/or rayon nonwoven sheet) using a binding process based on heating, ultrasound or other mechanism. Prior to application, a liquid or semisolid carrier composition containing ionic and non-ionc active agents and other optional electrolytes is applied to the nonwoven side of the device to activate the galvanic power source. The galvanic device is then pressed onto the user's face with the nonwoven side in direct contact with the skin. Alternatively, the active agents and other optional electrolyte may be incorporated in nonwoven layer during manufacturing process in an anhydrous state. In use, the device can be applied to water-wetted face, and the water will dissolve the active agents and electrolytes to activate the galvanic current. The anhydrous active agents may be in the form of dry powder immobilized onto the fibers of the nonwoven, or dissolved first in an organic solvent (e.g., polyethylene glycol, propylene glycol, glycerin, and/or alcohol) to form a non-conductive or very low conductive solution, which is absorbed in the nonwoven layer. [0166] The zinc anode materials may be manufactured with a wide variety of manufacturing process, including, but not limited to, metal processing, electroless deposition, electroplating, plasma spray, vacuum deposition, print processes such as screen printing using a zinc conductive ink, textile or nonwoven technologies. Similarly, other conductive metal materials, such as silver-silver chloride, silver-silver oxide, copper, magnesium, aluminum alloys of zinc, magnesium, copper and aluminum, may be manufactured into the aforementioned electrode forms using the manufacturing processes disclosed above. [0167] Another embodiment of the present invention is represented schematically in FIGS. 12 a, 12 b and 12 c. FIG. 12 a shows top view of device part 850 containing multiple, alternating positioned conductive electrodes 140 and 240. The conductive electrodes 140 and 240 may be made of the same materials, or preferably, may be made of dissimilar metals capable of forming galvanic couples, such as zinc and silver-silver chloride. The conductive electrodes 140 and 240 may be fabricated, for example, by printing or coating a conductive ink, or laminating a conductive tape or conductive film, onto an electrically nonconductive film 480. For example, silver/silver chloride-containing conductive ink may be used for screen-coating or printing for one type of the conductive electrodes. Zinc-containing conductive ink may be used for the other type conductive electrode. Other conductive materials in fine powder forms (e.g., carbon or graphite power or pure silver powder) may also be incorporated into these conductive inks to further improve the conductance of the conductive electrodes. [0168] The electrically nonconductive film 480 may be a thin and flexible polymer film that is inert and impermeable to water, organic solvents, and/or other ingredients in the carrier used in topical medication (e.g., ethyl alcohol, glycerol, and glycol). Examples of such polymers include, but are not limited to, polyethylene, polypropylene, polyvinyl acetate, polyurethane, silicone rubber, and polyvinyl chloride. The nonconductive film 480 is pre-perforated at certain locations in order to enable an electron communication (i) between the conductive electrode 140 and an electrically conductive connecting layer 440 and (ii) between the conductive electrode 240 and an electrically conductive connecting layer 460. The dotted lines show the positions of connecting layers 440 and 460 on the opposite side of the nonconductive film 480. [0169] Each perforation may be made of a single hole, slit, or a cluster of many small orifices. The correspondent perforation orifices 442 are under the conductive electrode 140. The correspondent perforation orifices 462 are under the conductive electrode 240. The manufacturing methods for the electrically conductive connecting layers 440 and 460 are similar to the fabrication methods for conductive electrodes 140 and 240. As shown in the FIG. 12 a, FIG. 12 b, and FIG. 12 c, the connecting layer 440 connects electrically all the conductive electrodes 140. Similarly, the connecting layer 460 connects electrically all the conductive electrodes 240 (not shown in FIG. 12 b). [0170] The two conductive electrodes are not restricted to being applied to a nonconductive film that is then integrated into the device. Instead, the electrodes may be applied directly to substrates that comprise the device. Substrates may include, but are not limited to, acrylate adhesives, mylar, glass, non-wovens (polyethylene, rayon, etc.) and ceramics. Other substrates may include flexible composites that are known in the art for fabricating flexible circuits. For example, kapton (polyimide film) or copper foil may be used. Application methods known in the art such as flexographic printing may be used to coat the conductive electrode inks directly onto non-wovens or adhesive layers. [0171] A means of incorporating the device part 855 into a device is shown in FIG. 13 a (top view of a functional device part 855) and FIG. 13 b (cross-section view of a device 900). The connecting layers 440 and 460 are connected with an electric conductive leads 450 with optional LED 422 and optional battery 420 (e.g., a thin flexible battery, a button battery, or a zinc-air hearing aid battery). In absence of the battery 420, the conductive electrodes 140 and 240 should preferably be aforementioned dissimilar metals in which the device works as a galvanic powered device. [0172] In one embodiment, LED 422 serves as a signaling purpose (e.g., to indicate the presence of electricity to a user). LEDs generally require a minimal voltage and current to work properly (e.g., commercially available LED's normally require higher than 1 volt to light them up). In a galvanic powered device, signaling LED 422 may require a galvanic couple materials capable of producing a voltage higher than 1 volt, such magnesium and silver-silver chloride couple. [0173] FIG. 13 b shows an example of a cross-section view of device 900 with the carrier substrate layer 120 (e.g., the carrier reservoir), functional device part 855, and backing cover layer/film 160, which is coated peripherally with adhesive 130. There may be a release liner layer/film placed over the adhesive layer 130 (not shown in the figure) and the carrier substrate layer 120. The carrier may be placed into the carrier substrate layer during manufacturing, or may be added to the carrier substrate layer prior to or during application. For example, wound exudates fluid may be absorbed into a nonwoven carrier substrate layer of a wound treatment device of the present invention to activate the device. The release liner layer is to be removed prior to use. [0174] Device 900 may be packaged individually, or in groups, in water-proof bags/packages for storage (not shown in the figure). There are several ways to activate the device. For example, in one embodiment, the carrier layer may be a nonconductive composition (e.g., an anhydrous composition with negligible conductive ions) when manufactured as an integral single device. Water may then be added to the composition by the user prior to the use to activating it (e.g., by applying the device onto a wetted skin). Alternatively, in one embodiment, part of the carrier is in an essentially nonconductive composition (e.g., an anhydrous composition with low conductive ions, such as a dry nonwoven layer manufactured on to the electrode layer). Such essentially nonconductive layer may contain active agents and other formulation aids/excipients and/or nonaquesous solvents such as glycols and glycerol. An aqueous composition or water-containing breakable pouch/reservoir made of a flexible-weak or hard-brittle polymer film is placed adjacent to the nonwoven layer within the water-proof bag/package. The breakable water-containing pouch can then be broken prior user (e.g., by pressing on it) to activate the device. [0175] Another embodiment of the present invention is one in which more than one device parts are connected in series, in parallel, or combination thereof. For example, two of the device parts 865 a and 865 b may be connected in series as shown in FIG. 14 a with optional LED 422 and optional battery 420. FIG. 14 b shows two device parts 460 a and 460 b connected in parallel (FIG. 14 b). [0176] The relative position of conductive electrodes 140 and 240 may vary depend on the use of the device. For example, when a more uniform electric current distribution in the carrier for the barrier membrane treatment is desired, a relatively parallel and/or equal distance positioning of conductive electrodes 140 and 240 may be chosen (an example shown in device part 865 a of FIG. 14 a). When a non-uniform electric current distribution in the carrier for the treatment of the barrier membrane is desired, a relatively non-parallel and/or unequal distance positioning of conductive electrodes 140 and 240 may be chosen (an example shown in device part 865 b of FIG. 14 a). [0177] When a connection in series is used for two device parts 865 a and 8565 b with zinc as one conductive electrode and silver-silver chloride electrode as the other in absence of the battery 420, the resulting galvanic voltage is about 2V, which is sufficient to light up some commercial LED's with required forward voltage (Vf) lower than 2V. The galvanic device of the present invention also generates a relatively high electric current that passes through the connecting lead 450 to satisfy the requirement of forward current (If) for those LED's. One way to increase the forward current is to reduce the distance (i.e., the gap) between the conductive electrodes 140 and 240. Another way is to increase the total size of the device part 865 a and/or 865 b by increasing the length and/or the number of conductive electrode pairs while keeping the other parameters the same. [0178] FIG. 15 shows a connection in series for four device parts 870 a, 870 b, 870 c, and 870 d. When conductive electrodes based on the Zn—Ag/AgCl galvanic couple are used for the conductive electrodes, an electric voltage of about 4V can be generated by this galvanic device. It should be noted while the total voltage may vary depending on the means of connecting multiple device parts, the barrier membrane under the device during application is still exposed to the same voltage defined by the galvanic couple used to make the conductive electrodes 140 and 240. For example, the skin under the electrodes of the device is subjected to about 1V of voltage if zinc is used as one conductive electrode and silver-silver chloride as the other regardless how many device parts 850 are connected in series. [0179] In another embodiment of the present invention, a patch, partial facial mask, or a full facial mask comprises multiple device parts, which may be connected individually within the device. Multiple devices may be located uniformly through out the facial mask, or strategically located only on the areas of the face that need more treatment, for example, on the forehead, the nose, the skin area around and under the eyes, the nasal labia, and the chin. Alternatively, the device parts may be connected together either in series or in parallel as shown in FIGS. 14 and 15, or in combination thereof. Some of the device parts may be individually connected, some connected in series, and other connected in parallel. [0180] In another embodiment of the present invention, the carrier layer 120 in FIG. 13 b (e.g., nonwoven layer, woven fabric layer, or sponge layer for holding liquid/semisolid carrier) may be divided by electrically insulating boundaries into separate regions. The advantage of such divided regions id that it enables application of different compositions to different skin areas. The divided regions on the same carrier layer is especially useful when the device is relatively large (e.g., for a partial or full facial mask) and multiple device parts are connected to form the device, such as in FIG. 14 a and FIG. 15. For example, in FIG. 15, if the carrier region in contact with each device part (i.e., device part 870 a, 870 b, 870 c, or 870 d) is electrically insulated from the other carrier layer regions, then the total current going through the lead 450 would be higher. The resulting higher current may be used for certain purposes, such as to drive one or more signaling devices (such one or more LEDs or a buzzer (e.g., miniature audio transformer). Polymers may be used to make the electrically insulating boundaries. For example, a boundary line of a molten polymer (low-melting polyethylene) may be applied over a nonwoven layer. A pressure-sensitive adhesive in a volatile solvent may also be used as it may also provide the additional benefit of aiding affixation of the patch/mask device to the skin. [0181] In another embodiment, the device of the present invention may be applied to the skin over one or more acupuncture points to administer electric current and/or active agents to treat the diseases and conditions of the barrier membranes and other body parts, including, but not limited to, acne, ulcers, wound healing enhancement, eczema, rosacea, psoriasis, herpes simplex, pain control, dysmenorrhea. The use of an electric current to stimulate acupuncture points on the skin is known. For example, U.S. Pat. No. 5,690,692 describes a device for generating biofrequency current to treat various diseases including acne and (ii) U.S. Patent Application 20040043062 describes a skin patch for acupuncture point application. The acupuncture points suitable for the application of the device of the present invention is described in a book by Stux, Berman and Pomeranz “Basics of Acupuncture”, 5th ED, 2003, published by Springer, New York. (e.g., page 307-309 for skin disorders). [0182] In another embodiment of the present invention, the conductive electrodes 140 and 240 are not uniformly arranged as shown previously in FIG. 12, instead, they may be arranged non-uniformly as shown in device part 865 with more conductive electrodes around the skin areas that need more treatment. [0000] Topical Compositions Containing Galvanic Pairs [0183] In one embodiment, the present invention features a topical composition containing a first conductive metal particulates (such as fine flakes, wires/fibers or metal-coated fibers) selected from zinc, aluminum, copper, and their alloys; and a second conductive metal particulates (such as fine flakes, wires/fibers or metal-coated fibers) selected from silver, copper, gold, and their alloys. The first and second metal particulates can be selected from aforementioned electrode materials to form galvanic couples. Upon contact, the first conductive metal and the second conductive metal form a galvanic pair, generates electric current, and electrochemically generates ions. In a further embodiment, the difference of the standard potentials of the first conductive metal and the second conductive metal is at least about 0.1 V, such as at least about 0.5 V. For example, upon contact with a first conductive metal that contains zinc (such as fine zinc wires, zinc flakes or polymer fibers coated with zinc) and a second conductive metal that contains silver (such as a fine silver wires/fibers, silver flakes, or polymer fibers coated with silver), the composition generates electric current and zinc ions within the topical composition. [0184] In one embodiment, the present invention features a topical composition containing particulates comprising at least two dissimilar metals in electric communication with each other to form galvanic power source unit (e.g., powders or small particles capable of generating galvanic current when in contact with an electrolyte medium or solution). Non-limiting examples of such galvanic particulates are small zinc powder or zinc flakes partially coated with silver/silver chloride, partial zinc coating on a conductive substrate such as a silver or silver/silver chloride coated polymer fibers/particles and solid or hollow glass or ceramic beads. In one embodiment, during storage, such galvanic particulates are placed in a container free of water/electrolyte solutions, or in a nonconductive solvent/solution. Upon application, the galvanic particulates come into contact with conductive solutions (e.g., an aqueous composition containing electrolytes or a body fluid) to be activated for electricity generation, and are deposited on to the barrier membrane surface to deliver electric current and/or active agents into the barrier membrane. [0185] In one embodiment, the longest dimension of such particulate is at least twice (e.g., at least five times) the shortest dimension of such particulate, thereby assisting the particulate to lay along its longer dimension on the barrier membrane. [0186] The composition may additionally contain an active agent, such as an anti-acne agent (such as salicylic acid, benzoyl peroxide, retinoic acid and/or retinol). The topical composition containing the first metal and the second metal is preferably a semi-solid dosage form (such as a gel, a hydrogel, a water-in-oil emulsion, an oil-in-water emulsion, a cream, a lotion, an ointment, a multi-emulsion, a liposome, and/or a microcapsule formulation), and may contain the aforementioned fluid suspending or fluid absorbing materials. The topical composition may be prepared as such that one of the conductive metal is formulated in a separate phase from other conductive metal, for example, the first conductive metal (e.g., zinc flakes) is formulated in the discontinuous oil phase of an oil-in-water emulsion (e.g., a cream), while the second conductive metal (e.g., silver flakes) is formulated in the continuous aqueous phase of the emulsion. The topical composition of the present invention may also further contain a humectant (such as glycerin, propylene glycol, polyethylene glycol, sorbitol and/or urea) and aforementioned electrolytes to maintain certain moisture level and conductivity of the skin. [0187] In one embodiment, during storage of such a topical composition, the first conductive metal and the second conduct metal are suspended substantially apart in a semi-solid composition (e.g., are not in contact with each other). Upon application to the membrane (such as the skin or mucosa) and partial drying of the liquid carrier, the contact of the first conductive metal and the second conductive metals results in galvanic couple formation and generation of electric current and metal ions of the first conductive metal, which provides benefits to the membrane such as antimicrobial, anti-inflammation, wound healing, iontophoretic delivery of active agents, tissue stimulation, and/or sebum reduction. [0188] In one embodiment, the wires/fibers, flakes of conductive metals, or polymer fibers coated with the conductive metals are fine enough that they can be suspended in the semi-solid compositions during storage. In a further embodiment, they are in elongated shapes. The advantages of elongated shapes of the conductive metals (e.g., fine wires/fibers, flakes and polymer fibers coated with the conductive metals) include a lower apparent density and, therefore, a better floating/suspending capability in the topical composition; a higher probability of connected with each other when low concentrations of the conductive metals are used; and a wider and deeper range of the membrane tissue (e.g., the skin) that the galvanic current travels through and provides the benefits to. [0189] In one embodiment, the first and second conductive metal particles are formulated into different compositions and are stored in separate compartments of a dual chamber dispensing package. For example, the less chemically stable (e.g., more oxidizable) zinc or its alloy particulates may be formulated in an anhydrous, essentially non-conductive composition with organic solvents such as polyethylene glycols, propylene glycol, glycerin, liquid silicone and/or alcohol, or other pharmaceutically-acceptable organic solvents. The more chemically stable (e.g., less oxidizable) silver and silver chloride particulates may be formulated in an aqueous composition. The active agents may be formulated into either composition depending on their chemical stability and solubility. In use, the compositions are dispensed from dual chamber package (e.g., dual chamber pump, tube, pouch, bottle, etc.) and mixed prior or during application to the skin to form galvanic couples in situ to generate galvanic current and to treat the skin conditions. [0190] In another embodiment, the aforementioned galvanic couples are manufactured as particulates to be incorporated into topical compositions. The particulates may be of any shape, including but not limited to, spherical or non-spherical particles or elongated or flattened shapes (e.g., metal or metal-coated spheres, hollow metal or metal-coated spheres, short metal-coated fibers or fabrics, and flakes), regular shapes (e.g., metal crystals), and irregular shapes (e.g., aggregated spheres). In one embodiment, the particulates have an average particle size of from about 1 micrometer to about 2 centimeters. What is meant by the particle size the maximum dimension in at least one direction. In one embodiment, the particulates have an average particle size of from about 1 micrometer to about 2 millimeters for non-elongated shapes. In another embodiment, the particulates with elongated shapes have an average particle size from about 10 micrometers to about 2 centimeters such as from about 100 micrometers to about 50 millimeters. For example, a polymer fiber of about 100 micrometers to about 10 millimeters in length may be coated partially with silver or silver-silver chloride on one end (or only on certain portions of the fiber), and zinc on the other end (or on the remaining portions). In another example, the polymer fiber is coated completely with the first conductive metal (e.g., silver-silver oxide or silver-silver chloride), and one end (or certain portions of the fiber) is coated with the second conductive metal (e.g., zinc or magnesium). [0191] In practice, silver-coated polymer fibers manufactured by Noble Fiber Technologies, Inc. (Clarks Summit, Pa.) may be coated with zinc using methods such as conductive zinc ink printing, electroplating, electroless deposition, vacuum deposition, and spray coating. Alternatively, a metallic zinc or magnesium particulate (e.g., bead or thin wire) may be coated at one end or at certain portions) with silver-silver oxide or silver-silver chloride. Spherical or non-spherical particles with an average particle size ranging from about one micrometer to about 5 millimeters may be partially covered with the first and second conductive metal coatings in a similar fashion. [0192] The coating methods for such first and second conductive metals in preparing the galvanic couples may be electroless deposition, electric plating, vacuum vapor deposition, arc spray, conductive metal ink, and other known metal coating methods commonly used in electronic and medical device manufacturing processes. The galvanic couple particulates are preferably stored in aforementioned anhydrous forms, e.g., as a dry powder or immobilized in a fabric with binding agents, or as an essentially anhydrous non-conducting organic solvent composition (e.g., dissolved in polyethylene glycols, propylene glycol, glycerin, liquid silicone, and/or alcohol). The galvanic particulates have great versatility in applications, and can be used in many consumer and medical products such as patches, bandages, masks, garments, cloths, socks, head caps, gloves, mittens, bed sheets (e.g., by immobilized into the carrier or fabric), spread-on facial mask composition (such as a paste, cream or gel), creams, lotions, gels, shampoos, cleansers, powders, or incorporated into personal and medical products such as toothbrushes, dental flosses, periodontal implants or inserts, orthodontic braces, buccal patches, ocular inserts or implants such as contact lenses, nasal implants or inserts, wound dressings, diapers, sanitary napkins, dry wipes, pre-moistened wipes (with aforementioned anhydrous solvents), tampons, and rectal and vaginal suppositories. The galvanic particulates may also be incorporated into transdermal drug delivery patches to enhance drug penetration into the skin by iontophoresis and to reduce skin irritation by electric stimulation and electrically generated beneficial ions such as zinc ions. EXAMPLE 1 Carriers [0193] Examples of several carriers, including the weight percentage range of the ingredients of such carriers, are set forth in Table 1. TABLE 1 Percent by Weight of the Carrier Component No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 Salicylic acid 0.1-10 2 2 0 0 0.1-10 Benzyl peroxide 0 0 0 0.5-10 0 0 Sulfur 0 0 0 0 3 3 Resorcinol 0 0 0 1 1 1 Benzalkonium 0-2 0.1 0.1 0-2 0-2 0-2 chloride Benzethonium or 0-2 0 0 0-2 0-2 0-2 methylbezethonium chloride Cetylpyridium 0-2 0.1 0.1 0-2 0-2 0-2 chloride Phospholipid CDM 0-40 5 5 0-40 0-40 0-40 Hydrogen peroxide 0-30 0 3 0-30 0-30 0-30 Buffer (citrate, 0-10 2 2 0-10 0-10 0-10 lactate, or phosphate salts of sodium, potassium, or lithium Gelling agent 0-20 5 5 0-20 0-20 0-20 (e.g., polyacrylates, cellulose, natural or synthetic gums, or polyacrylamide) Chelating agent 0-2 0.1 0.1 0-2 0-2 0-2 (e.g., EDTA) Propylene glycol 0-30 20 15 0-30 0-30 0-30 Polyethylene 0-50 0 0 0-50 0-50 0-50 glycol Polypropylene 0-40 0 0 0-40 0-40 0-40 glycol Ethyl alcohol 0-50 0 15 0-50 0-50 0-50 Isopropyl alcohol 0-50 0 0 0-50 0-50 0-50 Dimethyl 0-20 2 0 0-20 0-20 0-20 isosorbide Isopropyl 0-30 1 1 0-30 0-30 0-30 myristate Purified water Qs to Qs to Qs to Qs to Qs to Qs to 100 100 100 100 100 100 [0194] In order to evaluate the proposed mechanism of action for the electrochemically generated beneficial agents, an in vitro microbiologic study was conducted to investigate effect of electrolysis on P. acne inhibition in certain electrochemical systems; and an in vivo study was conducted in human volunteers using a commercial iontophoresis device. EXAMPLE 2 In Vitro Inhibition of P. acnes by Electrolysis [0195] A BacT/ALERT system (BioMerieux, Inc., Durham, N.C.) was used in the P. acnes inhibition experiment. Briefly, 40 ml of an anaerobic casein and soy based broth culture medium in a bottle (BacT/ALERT SN, Organon Tekniks Corp., Durham, N.C.) was inoculated with P. acnes. The fully automated BacT/ALERT system was used to detect P. acnes growth over a 14-day study at 35° C. by continuous monitoring of CO2 production using an optical calorimetric sensory system. A selected pair of the electrodes (Table 2, Columns 2 and 3) was disinfected with 70% isopropyl alcohol, and inserted through the rubber stopper into the culture medium in a nitrogen glove box. Some electrodes were connected to the poles of a battery (either 1.5 or 3V as indicated in Table 2, Column 3) for 30 minutes. The electrodes were then immediately removed from the BacT/ALERT bottle, which was then placed into the automated incubation and monitoring system for two weeks. Other elecrodes (i.e., Nos. 3 & 5 in Table 2), were not connected to an external battery, but rather were directly connected to each other at their ends outside the BacT/ALERT bottle to form galvanic couple. The electrodes of these galvanic couples (i.e., Nos. 3 & 5) remained in contact with the culture medium in the bottle during the 14-day study. [0196] Zinc as the positive electrode (anode), with various materials as the negative electrode (cathode), was evaluated through the test conditions 1 to 7 (No.1-7 in Column 1). Column 4 shows the voltage applied to the conductive electrode by the external battery. However, by simply connecting two conductive electrode materials, a voltage was also generated just from the galvanic pair. For example, zinc-silver/silver chloride galvanic couple has a voltage of 0.9849V or about 1V (Zn2++2e−=Zn, standard potential: −0.7626V, and AgCl+e−=Ag+ Cl−, standard potential: 0.2223V) and zinc-copper galvanic couple has a voltage of about 1.1-1.3V (Cu2++2e−=Cu, standard potential: 0.340V, and Cu++e−=Cu, standard potential: 0.520V) Reference: Electrochemistry Handbook, 1995, Table 14.1, McGraw-Hill, Inc. New York, N.Y.). [0197] In the test condition No. 7, the electrodes (i.e., zinc-silver/silver chloride galvanic couple) were taken from a commercial iontophoresis device (IontoPatch, SP, Birch Point Medical, Inc., Oakdale, Minn.). The IontoPatch is an iontophoresis device powered by a galvanic couple “battery strip” made of zinc and silver/silver chloride in a bandage-like device. In this experiment, the “battery strip” in the IontoPatch was taken out of the bandage-like device, and placed into the BacT/ALERT bottle. The electrodes of the commercial zinc-silver/silver chloride galvanic couple (No. 7) remained in the BacT/ALERT bottle through out the entire two-week experiments. Test conditions of Nos. 15-17 were positive controls (i.e., without electrodes): Test condition No. 15 used a concentrated P. acne culture that was used to inoculate the rest of the culture medium in each BacT/ALERT bottle to P. acnes counts of 106 per ml and Test conditions No. 16 and No. 17 used the inoculated culture medium of P. acnes counts of 106 per ml (with the rubber stoppers of No. 16 additionally being punctured in a way similar to the rest of electrode-tested conditions in order to eliminate any false P. acnes inhibition results due to potential environmental oxygen entry into the test bottle and affecting anaerobic P. acnes growth). TABLE 2 Voltage applied by Average connected time to to a Positive Number battery P. acnes positive/ Positive Negative or Growth number No. Electrode Electrode batteries (days) tested 1 Zinc Silver/Silver 3 V — 0/3 Chloride 2 Zinc Zinc 3 V — 0/1 3 Zinc Copper Nonea — 0/2 4 Zinc Copper 1.5 V — 0/1 5 Zinc Silver/Silver Nonea — 0/2 Chloride 6 Zinc Silver/Silver 1.5 V — 0/2 Chloride 7 Zinc Silver/Silver Nonea —b 2/6 Chloride 8 Copper Silver/Silver 3 V — 0/3 Chloride 9 Copper Copper 3 V — 0/2 10 Platinum Silver/Silver 3 V 1.6 2/2 Chloride 11 Platinum Platinum 3 V 1.1 1/1 12 Silver Silver/Silver 3 V 5.7c 2/3 Chloride 13 Silver Silver 3 V 2.8d 2/2 14 Silver/Silver Silver/Silver 3 V 3.0 2/2 Chloride Chloride 15 None None None 0.8 2/2 16 None None None 1.4 2/2 17 None None None 1.3 2/2 aThe conductive metal electrodes were not connected to any battery, but to each other. Therefore, there is a voltage across the two electrode dictated by the galvanic pair. bA total of 6 samples were tested; 4 negative and 2 positive (0.6d & 0.8d); the positive ones were very likely due to bacterial contamination since they were detected faster then the positive control samples (Nos. 16 & 17), and therefore were omitted. cOut of 3 samples, two positive (4.1d & 7.3d) were averaged The zinc anode was surprisingly found to almost completely inhibit P. acne growth during the 14-day incubation study at the all of the voltage conditions tested (Nos. 1-7; in No. 7, two of the six commercial galvanic couples showed positive P. acnes growth probably due bacterial contamination, see Note C of Table 2). The copper anode was also found to significantly inhibit P acnes growth (Nos. 8-9). Under these experimental conditions, the platinum anode showed little P. acne inhibition effect and the silver or silver/silver chloride anodes provided only a weak P. acne inhibition. Since all the positive control conditions (Nos. 15-17) showed positive P. acnes growth less than two days after the beginning of the study, the negative P. acnes growth can be attributed to the inhibition effect of the electrochemically generated species or electric current passage through the culture medium. Because electric current passage in Nos. 10-14 failed to show strong P. acnes inhibition as those in Nos. 1-9, the observed bacterial inhibition in Nos. 1-9 were likely due to certain electrochemical reactions occurred at the anode, namely, when zinc and copper were used as the anode. It was also unexpected that the silver ions released from silver or silver/silver chloride anode under these experimental conditions failed to show the same P. acnes inhibition (Nos. 12-14), since silver ion is well-known anti-microbial agent. See. e.g., Spacciapoli et al. (“Antimicrobial activity of silver nitrate against periodontal pathogens.”, J Periodontal Res 36: 2, 108-13, Apr., 2001). It was surprising that, in the absence of external battery (Nos. 3, 5 and 7), a pair of electrodes of galvanic couple with zinc as anode were sufficient to inhibit P. acnes growth during the entire two week study. EXAMPLE 3 In Vitro Electrode-Salicylic Acid Compatibility [0198] The following experiment was conducted to determine the compatibility of electrodes with salicylic acid. A pair of test electrodes was immersed in 5 ml of 1.5% salicylic acid solution (solvent 50% ethanol/50% water). A pre-determined voltage was applied to the electrodes (by connecting the electrodes to a battery or batteries) for certain length of time as indicated in Table 3. Observations were made on color change of the test solution. [0199] The solution with the zinc anode showed no discoloration, indicating good compatibility with salicylic acid during the passage of electric current. Use of the platinum anode unexpectedly resulted in discoloration, indicating incompatibility with salicylic acid under this experimental condition. TABLE 3 Electrode Material Test Observation Anode Cathode Voltage Duration Solution color (+) (−) (V) (min) change Platinum Platinum 3 10 Colorless → yellow Platinum Platinum 9 10 Colorless → brown Zinc Platinum 1.5 10 No color change Zinc Platinum 3 10 No color change Zinc Platinum 9 30 No color change EXAMPLE 4 In Vivo Human Iontophoresis Study [0200] An in vivo study was conducted in human volunteers using a commercial iontophoresis device (IontoPatch®, Model: SP, Birch Point Medical Inc., North Oakdale, Minn.). The study recruited the healthy female volunteers with oily skin, aged from 20-45 years. The sebumeter reading from each subject's forehead was at least greater than 150 mg/cm2/hr. The study was blind and controlled. Briefly, an IontoPatch® with a voltage of 1 volt, an operating current of 0.06 mA, and an active treatment area of 1.25 in2, was applied to the treatment site of the human subject (e.g. forehead). The positive electrode and negative consisted of zinc and silver/silver chloride (Ag/AgCl)material, respectively. Both electrodes were filled with saline (0.9% NaCl). As soon as the saline solution was added into the different electrodes, the electric patch begin to function. The patch was left on the treatment area overnight (e.g., approximately 8 hours). [0201] The following evaluations were conducted: (i) the effects of electrolysis on the skin condition were monitored using a normal photography and (ii) The change in p. acnes counts was determined through analyzing the cup wash solution for the treatment site before and after wearing the patch overnight. The cup wash micro sampling procedure was performed as follows: a cylindrical cup (2.1 cm diameter and 2.5 cm height) having two open ends was fastened onto the treatment area. The treatment area inside the cylinder was then washed with 2 ml of cleansing buffer (sterile 0.075M Phosphate Buffer containing 0.1% Triton X-100) while the same area with a sterile polished glass. The wash solution was then collected. This washing procedure was then repeated. The two collected samples were pooled and used in the P-acnes analysis. [0202] The P. acnes counts were determined by Spiral Plating the scrub samples anaerobically in Actinomyces Agar for 5 days, and the predominant contaminants on the spiral plates were Gram stained and identified using the VITEK System. Using an automated colony counter, the P-acne count per mL of each sample buffer was determined. [0203] After only one overnight patch application, P. acne quantification measurement on the treatment area shows a 45% P. acne reduction relative to the baseline under the zinc anode and 30% under the Ag/AgCl cathode. After four consecutive overnight patch applications, photo images displayed the clear evidences of significant reduction in the color and size of post-acne hyperpigmentation spot under the zinc electrode. This test subject had a post-acne hyperpigmentation spot at the test skin site. The appearance of the hyperpigmented spot was improved from a very dark color to a lighter color. [0204] Also, after four consecutive overnight patch applications, photo images also displayed the evidence of significant reduction in the color and size of an acne pimple under the Ag/AgCl electrode. This test subject had an acne pimple at the test skin site. The redness of the pimple was rapidly reduced from very red color to become almost invisible while the pimples at the non-treated skin area remained largely unchanged. EXAMPLE 5 In Vivo Human Iontophoresis Study Using Histamine Hydrochloride as Marker [0205] An in vivo study was conducted in three human volunteers using a galvanic zinc-silver/silver oxide device to deliver histamine hydrochloride as a marker into the skin. Histamine-induced skin erythema and itchiness were recorded during and after the study. The study recruited two healthy male and one female volunteers with ages ranging 41 to 49 years. The galvanic devices were prepared by cutting a thin zinc foil (0.25 mm thick, Alfa Aesar, Word Hill, Mass.) into rectangular piece (2.5 cm wide & 3 cm long). A silver ink (Silver Print, M.G. Chemicals, Toronto, Ontario, Canada) was painted onto one side of the zinc foil as a 0.5 cm wide stripe along the long-axis at the center. The ink was air-dried to produce the silver electrode stripe on the zinc foil. Two rectangular adhesive Scotch® tape stripes of 0.5 cm wide and 3 cm long were placed on the both sides of the silver electrode stripe creating an electric insulating gap on the surface (electrode gap=0.5 cm). A rectangular piece of nonwoven fabric (50% Rayon/50% PET, 75 gsm, PGI Polymer Group Inc., Landisville, N.J.) of 3 cm wide and 3.5 cm long was placed over the zinc-silver electrode side of the zinc foil. A rectangular adhesive backing film of 4 cm wide and 5 cm long was affixed to the opposite side of the zinc foil to complete the zinc-silver galvanic device. [0206] A second type of the zinc-silver galvanic device without and electric insulating gap on the surface(electrode gap=0 cm) was prepared by simply omitting the addition of the adhesive Scotch® tape. A third type (control) patch was prepared by using only the zinc foil, the nonwoven pad, and the adhesive backing film to construct the device. [0207] To begin histamine iontophoresis, 0.8 ml aqueous solution of 0.1% histamine hydrochloride (Sigma-Aldrich, St. Louis, Mo.) was added to each device, which was then affixed to the forearm skin of each volunteer for 30 minutes. [0208] At the end of the study, red spots (histamine induced erythema) appeared under both zinc-silver galvanic patch devices, which disappeared within about one half hour. A close examination showed the red spots around the hair follicles. There was also itchiness reported at the galvanic patch sites reported during the patch application. In contrast, there were no change in skin color under, nor any itchiness reported with, the control patch devices. EXAMPLE 6 In Vivo Human Iontophoresis Study Using Histamine Hydrochloride with a Galvanic Nose Patch Comprising Zinc Mesh [0209] As a continuation of the human in vivo study in the previous example, a galvanic patch device (designated here as “Test Device D”) comprising a zinc mesh (diamond openings of 1 cm long & 0.4 cm wide, Dexmet Corporation, Naugatuck, Conn.) instead of zinc foil was prepared with the same dimension and procedure as the galvanic device (gap electrode=0) in EXAMPLE 5. The device thus prepared resembled to the design shown in FIG. 11 with three parallel electrodes: the silver electrode in the center and zinc electrodes on both sides. Two male volunteers participated this study using a similar test conditions as in EXAMPE 5. One Test Device containing 0.8 ml of 0.1% histamine hydrochloride was applied to the nose of each volunteer for 30 minutes. Itchiness was reported within 5 minutes of the nose patch application, indicating rapid delivery of histamine into the relatively larger skin pores on the nose. For both test subjects, pronounced erythema was observed at the skin site under the nose patch after patch removal at the end of the study, in comparison to the study conducted on the forearm skin. [0210] It is understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2182485 *Feb 15, 1939Dec 5, 1939Murdock Fred JChairUS4034750 *Apr 22, 1975Jul 12, 1977Maurice SeidermanElectrochemically linking collagen fibrils to animal tissueUS4067342 *Apr 6, 1976Jan 10, 1978Medtronic, Inc.Tape electrodeUS4211222 *Sep 8, 1978Jul 8, 1980Robert TapperIontophoretic burn-protection methodUS4223661 *Aug 13, 1979Sep 23, 1980Sergev Sergius SPortable diver heat generating systemUS4305390 *Jun 18, 1979Dec 15, 1981Massachusetts Institute Of TechnologyMethod for generating oxygen in an excited electronic state and inactivation of microorganismsUS4372296 *Nov 26, 1980Feb 8, 1983Fahim Mostafa STreatment of acne and skin disorders and compositions thereforUS4474570 *Jul 8, 1982Oct 2, 1984Kabushikikaisya Advance Kaihatsu KenkyujoIontophoresis deviceUS4606354 *May 21, 1985Aug 19, 1986Ezekiel Jacob JGold coated carbon implant and method of treating arthritis therewithUS4689039 *Jul 1, 1986Aug 25, 1987Ken HayashibaraElectrotherapeutic apparatus for iontophoresisUS4754164 *Jun 30, 1984Jun 28, 1988Unisys Corp.Method for providing automatic clock de-skewing on a circuit boardUS4767401 *Aug 26, 1982Aug 30, 1988Maurice SeidermanIontophoretic administration of ionizable or polar medicaments to a mammalian bodyUS4842477 *Dec 24, 1986Jun 27, 1989General Electric CompanyActive clearance controlUS4852571 *Sep 3, 1987Aug 1, 1989Marquette ElectronicsDisposable biopotential electrodeUS4957480 *Feb 2, 1988Sep 18, 1990Universal Health Products, Inc.Method of facial toningUS4979938 *May 11, 1989Dec 25, 1990Iomed, Inc.Method of iontophoretically treating acne, furuncles and like skin disordersUS5122418 *Oct 4, 1990Jun 16, 1992Shiseido Company Ltd.Composite powder and production processUS5147297 *May 7, 1990Sep 15, 1992Alza CorporationIontophoretic delivery deviceUS5224927 *Nov 1, 1990Jul 6, 1993Robert TapperIontophoretic treatment systemUS5314502 *Oct 2, 1992May 24, 1994Alza CorporationIontophoretic delivery deviceUS5352315 *Nov 5, 1993Oct 4, 1994Ludlow CorporationBiomedical electrodeUS5356632 *Sep 12, 1991Oct 18, 1994S.I. Scientific Innovations Ltd.Transdermal drug delivery deviceUS5380272 *Jun 16, 1993Jan 10, 1995Scientific Innovations Ltd.Transcutaneous drug delivery applicatorUS5405310 *Dec 13, 1993Apr 11, 1995Yoo; Tae W.Acupressure gloves adhered acupressure devicesUS5415628 *Aug 2, 1993May 16, 1995Alza CorporationIontophorett drug deliveryUS5443441 *Nov 12, 1993Aug 22, 1995De Claviere; Anne MarieApparatus and method for transdermal delivery of cosmetic compositionsUS5466217 *Apr 4, 1994Nov 14, 1995Alza CorporationIontophoretic drug delivery apparatusUS5470349 *Jun 16, 1992Nov 28, 1995Courage & Khazaka Electronic GmbhDevice for treating inflammatory skin changes in the initial stage, and method for using sameUS5503840 *Oct 20, 1993Apr 2, 1996E. I. Du Pont De Nemours And CompanyAntimicrobial compositions, process for preparing the same and useUS5595750 *Dec 21, 1994Jan 21, 1997E. I. Du Pont De Nemours And CompanyAntimicrobial particles of silver and barium sulfate or zinc oxideUS5624415 *Apr 24, 1995Apr 29, 1997Alza CorporationReduction of skin irritation and resistance during electrotransportUS5624425 *Apr 5, 1995Apr 29, 1997The Procter & Gamble CompanyLocalized application of fine denier fibers onto a spunbonded web for optimization of leg cuff hydrophobicity in diapers and padsUS5678545 *May 4, 1995Oct 21, 1997Stratbucker; Robert A.Anisotropic adhesive multiple electrode system, and method of useUS5688233 *Nov 2, 1995Nov 18, 1997Genetronics, Inc.Electronincorporation enhanced transdermal delivery of moleculesUS5817044 *Jul 28, 1994Oct 6, 1998Becton Dickenson And CompanyUser activated iontophoertic deviceUS5830175 *Jul 24, 1997Nov 3, 1998Becton Dickinson And CompanyIontophoretic drug delivery system, including disposable patchUS5928185 *Jan 24, 1996Jul 27, 1999SanofiIontophoresis device for the transcutaneous delivery of an active principle such as an anionic oligosaccharideUS5935598 *Jun 18, 1997Aug 10, 1999Becton Dickinson Research CenterIontophoretic delivery of cell adhesion inhibitorsUS5955017 *Jan 29, 1997Sep 21, 1999Nordica S.P.A.Method for producing shoe soles by injection-moldingUS5955067 *Jul 23, 1996Sep 21, 1999Oge; ErayPotassium-containing composition useful in the treatment of acne, psoriasis and seborrheaUS5961483 *Jun 18, 1997Oct 5, 1999Sage; Burton H.Iontophoretic delivery of cell adhesion inhibitorsUS5974344 *Mar 2, 1998Oct 26, 1999Shoemaker, Ii; CharlesWound care electrodeUS5993435 *Aug 24, 1998Nov 30, 1999Alza CorporationDevice and method of iontophoretic drug deliveryUS6004309 *Apr 18, 1997Dec 21, 1999Alza CorporationMethod and apparatus for controlled environment electrotransportUS6078842 *Dec 23, 1997Jun 20, 2000Elan Corporation, PlcElectrode and iontophoretic device and methodUS6104950 *Aug 14, 1995Aug 15, 2000Hisamitsu Pharmaceutical Co., Inc.Plaster structure for iontophoresisUS6157858 *Dec 23, 1997Dec 5, 2000Elan Pharma International LimitedDevice for the delivery of a substance to a subject and improved electrode assemblyUS6169920 *Oct 11, 1994Jan 2, 2001Alza CorporationIontophoretic drug delivery apparatusUS6185453 *Jun 18, 1997Feb 6, 2001Dupont Pharmaceuticals CompanyIontophoretic delivery of integrin inhibitorsUS6238381 *Jan 30, 1996May 29, 2001Robert TapperIontophoretic treatment systemUS6289241 *Jun 10, 1998Sep 11, 2001Alza CorporationMethod and apparatus for controlled environment electrotransportUS6306384 *Oct 1, 1996Oct 23, 2001E-L Management Corp.Skin battery cosmetic compositionUS6317629 *Jun 1, 1993Nov 13, 2001Alza CorporationIontophoretic drug delivery apparatusUS6421561 *Jul 11, 2000Jul 16, 2002Birch Point Medical, Inc.Rate adjustable drug delivery systemUS6522918 *Feb 9, 2000Feb 18, 2003William E. CrispElectrolytic deviceUS6582416 *Dec 16, 1999Jun 24, 2003Robert TapperIontophoretic treatment systemUS6584349 *Nov 17, 1997Jun 24, 2003Vyteris, Inc.Low cost electrodes for an iontophoretic deviceUS6653014 *May 30, 2001Nov 25, 2003Birch Point Medical, Inc.Power sources for iontophoretic drug delivery systemsUS6654635 *Feb 19, 1999Nov 25, 2003Hisamitsu Pharmaceutical Co., Inc.Iontophoresis deviceUS6738662 *Nov 21, 2000May 18, 2004Steven R. FrankElectrolytic substance infusion deviceUS6745071 *Feb 21, 2003Jun 1, 2004Birch Point Medical, Inc.Iontophoretic drug delivery systemUS6775570 *Apr 18, 2002Aug 10, 2004Ceramatec, Inc.Iontophoretic treatment deviceUS6821281 *Sep 14, 2001Nov 23, 2004The Procter & Gamble CompanyMicrostructures for treating and conditioning skinUS6855117 *Aug 1, 2001Feb 15, 2005Johnson & Johnson Consumer Companies, Inc.Method of treating the skin of a subjectUS6866856 *Dec 31, 2002Mar 15, 2005Avon Products, Inc.Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosisUS6890553 *Jul 7, 2000May 10, 2005Johnson & Johnson Consumer Companies, Inc.Exothermic topical delivery deviceUS6989156 *Apr 23, 2002Jan 24, 2006Nucryst Pharmaceuticals Corp.Therapeutic treatments using the direct application of antimicrobial metal compositionsUS7008647 *Apr 23, 2001Mar 7, 2006Nucryst Pharmaceuticals Corp.Treatment of acneUS7457667 *Feb 19, 2004Nov 25, 2008Silverleaf Medical Products, Inc.Current producing surface for a wound dressingUS7476221 *Oct 14, 2003Jan 13, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating acne and rosacea with electrochemically generated zinc ionsUS7476222 *Jun 23, 2004Jan 13, 2009Johnson & Johnson Consumer Companies, Inc.Methods of reducing the appearance of pigmentation with galvanic generated electricityUS7477938 *Jun 30, 2003Jan 13, 2009Johnson & Johnson Cosumer Companies, Inc.Device for delivery of active agents to barrier membranesUS7477939 *Jun 23, 2004Jan 13, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating a wound with galvanic generated electricityUS7477940 *Jun 23, 2004Jan 13, 2009J&J Consumer Companies, Inc.Methods of administering an active agent to a human barrier membrane with galvanic generated electricityUS7479133 *Jun 23, 2004Jan 20, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating acne and rosacea with galvanic generated electricityUS7480530 *Jun 30, 2003Jan 20, 2009Johnson & Johnson Consumer Companies, Inc.Device for treatment of barrier membranesUS7495146 *May 17, 2005Feb 24, 2009Vivo Ltd. PartnershipWound dressingUS7507228 *Jun 30, 2003Mar 24, 2009Johnson & Johnson Consumer Companies, Inc.Device containing a light emitting diode for treatment of barrier membranesUS8025673 *Jul 13, 2000Sep 27, 2011Nikolai Grigorievich LyapkoNeedle for use in reflexotherapy, and an applicator using the sameUS8150525 *Aug 27, 2008Apr 3, 2012Johnson & Johnson Consumer Companies, Inc.Treatment of hyperhydrosisUS8239017 *Nov 17, 2008Aug 7, 2012Johnson & Johnson Consumer Companies, Inc.Device for treatment of barrier membranesUS20030039860 *Nov 21, 2001Feb 27, 2003Cheon Jin WooMethod for synthesis of core-shell type and solid solution alloy type metallic nanoparticles via transmetalation reactions and applications of sameUS20030100884 *Nov 26, 2001May 29, 2003Deagle William R.Iontophoresis disc pain blockerUS20040167461 *Jan 15, 2004Aug 26, 2004Zvi NitzanDermal patchUS20040237236 *Jun 30, 2004Dec 2, 2004Gavney James A.Squeegee device and systemUS20040265395 *Jun 30, 2003Dec 30, 2004Ying SunDevice for delivery of reducing agents to barrier membranesUS20040267169 *Jun 30, 2003Dec 30, 2004Ying SunDevice for treatment of barrier membranesUS20040267189 *Oct 23, 2002Dec 30, 2004Daniela MavorDevice and method for controlled delivery of active substance into the skinUS20040267231 *Jun 30, 2003Dec 30, 2004Ying SunDevice for delivery of oxidizing agents to barrier membranesUS20040267232 *Jun 30, 2003Dec 30, 2004Ying SunDevice for delivery of active agents to barrier membranesUS20040267236 *Jun 30, 2003Dec 30, 2004Ying SunDevice containing a light emitting diode for treatment of barrier membranesUS20040267237 *Oct 14, 2003Dec 30, 2004Ying SunMethods of treating acne and rosacea with electrochemically generated zinc ionsUS20050004508 *Jun 23, 2004Jan 6, 2005Ying SunMethods of reducing the appearance of pigmentation with galvanic generated electricityUS20050004509 *Jun 23, 2004Jan 6, 2005Ying SunMethods of administering an active agent to a human barrier membrane with galvanic generated electricityUS20050004550 *Jun 23, 2004Jan 6, 2005Ying SunMethods of treating a wound with galvanic generated electricityUS20050010161 *Jun 23, 2004Jan 13, 2005Ying SunMethods of treating acne and rosacea with galvanic generated electricityUS20050010192 *Jun 23, 2004Jan 13, 2005Ying SunMethods of treating pores on the skin with electricityUS20050015042 *Jun 23, 2004Jan 20, 2005Ying SunMethods of exfoliating the skin with electricityUS20070122461 *Feb 3, 2006May 31, 2007Tse-Hao KoAntimicrobial compositions and wound dressings* Cited by examinerNon-Patent CitationsReference1 *WO 1994/016765A1, Gross, 1994. WO 2000/047274A1, Brown et al., 2000. WO 2000/037071A1, Wulf, 2000. WO 1995/023588A1, Kastin et al., 1995.2 *WO 1995/023588, Kastin et al., date: 1995.3 *WO 2000/037071, Wulf, date: 2000.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS7457667Feb 19, 2004Nov 25, 2008Silverleaf Medical Products, Inc.Current producing surface for a wound dressingUS7476221Oct 14, 2003Jan 13, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating acne and rosacea with electrochemically generated zinc ionsUS7477938Jun 30, 2003Jan 13, 2009Johnson & Johnson Cosumer Companies, Inc.Device for delivery of active agents to barrier membranesUS7477939Jun 23, 2004Jan 13, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating a wound with galvanic generated electricityUS7479133Jun 23, 2004Jan 20, 2009Johnson & Johnson Consumer Companies, Inc.Methods of treating acne and rosacea with galvanic generated electricityUS7486989Jun 30, 2003Feb 3, 2009Johnson & Johnson Consumer Companies, Inc.Device for delivery of oxidizing agents to barrier membranesUS7662176Aug 18, 2006Feb 16, 2010Vomaris Innovations, Inc.Footwear apparatus and methods of manufacture and useUS7672719Feb 18, 2005Mar 2, 2010Vomaris Innovations, Inc.Batteries and methods of manufacture and useUS7744932Mar 14, 2008Jun 29, 2010Mary Kay Inc.Magnolia extract containing compositionsUS7813806Oct 13, 2008Oct 12, 2010Vomaris Innovations, Inc.Current producing surface for treating biologic tissueUS7890164Sep 14, 2006Feb 15, 2011Tti Ellebeau, Inc.Iontophoresis deviceUS7904146 *Nov 9, 2007Mar 8, 2011Travanti Pharma Inc.Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisionsUS7973058Jul 28, 2008Jul 5, 2011Nupathe, Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsUS8062783Nov 29, 2007Nov 22, 2011Tti Ellebeau, Inc.Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devicesUS8084063Oct 19, 2010Dec 27, 2011Mary Kay Inc.Magnolia extract containing compositionsUS8084066Feb 16, 2010Dec 27, 2011Mary Kay Inc.Magnolia extract containing compositionsUS8150525Aug 27, 2008Apr 3, 2012Johnson & Johnson Consumer Companies, Inc.Treatment of hyperhydrosisUS8155737Jun 19, 2008Apr 10, 2012Nupathe, Inc.Pharmacokinetics of iontophoretic sumatriptan administrationUS8197844 *Jun 8, 2007Jun 12, 2012Activatek, Inc.Active electrode for transdermal medicament administrationUS8224439Feb 1, 2010Jul 17, 2012Vamaris Innovations, Inc.Batteries and methods of manufacture and useUS8239017Nov 17, 2008Aug 7, 2012Johnson & Johnson Consumer Companies, Inc.Device for treatment of barrier membranesUS8295922Aug 7, 2006Oct 23, 2012Tti Ellebeau, Inc.Iontophoresis deviceUS8295924Jan 20, 2011Oct 23, 2012Teikoku Pharma Usa, Inc.Transdermal systems for the delivery of ionic agents directly to open wounds and surgically repaired incisionsUS8311624 *Sep 25, 2009Nov 13, 2012The Cleveland Clinic FoundationApparatus and method for delivering a therapeutic agent to ocular tissueUS8366600Jun 19, 2008Feb 5, 2013Nupathe Inc.Polyamine enhanced formulations for triptan compound iontophoresisUS8386030Aug 8, 2006Feb 26, 2013Tti Ellebeau, Inc.Iontophoresis deviceUS8445036Dec 13, 2011May 21, 2013Mary Kay Inc.Magnolia extract containing compositionsUS8470853May 11, 2011Jun 25, 2013Nupathe Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsUS8475689Oct 31, 2006Jul 2, 2013Johnson & Johnson Consumer Companies, Inc.Topical composition containing galvanic particulatesUS8702665 *Apr 12, 2011Apr 22, 2014Kci Licensing, Inc.Reduced-pressure sources, systems, and methods employing a polymeric, porous, hydrophobic materialUS8734421Jun 23, 2004May 27, 2014Johnson & Johnson Consumer Companies, Inc.Methods of treating pores on the skin with electricityUS8744567Nov 8, 2010Jun 3, 2014Johnson & Johnson Consumer Companies, Inc.Galvanic skin treatment deviceUS8758839Nov 16, 2011Jun 24, 2014Mary Kay Inc.Magnolia extract containing compositionsUS8821945Jul 7, 2009Sep 2, 2014Fe3 Medical, Inc.Method for transdermal iontophoretic delivery of chelated agentsUS8845612Aug 10, 2010Sep 30, 2014Nupathe Inc.Methods for iontophoretically treating nausea and migraineUS8846161Jul 16, 2010Sep 30, 2014Brigham Young UniversityHydrophobic coating and methodUS8862223Jan 18, 2008Oct 14, 2014Activatek, Inc.Active transdermal medicament patch and circuit board for sameUS8892199 *Oct 18, 2007Nov 18, 2014Buckeye PharmaceuticalsChemical compound delivery device and methodUS8923961May 13, 2011Dec 30, 2014The Cleveland Clinic FoundationElectrode assembly for delivering a therapeutic agent into ocular tissueUS8956345 *Mar 31, 2010Feb 17, 2015Simone Nadia LEONARDI KADERMethod and appliance for cosmetic skincareUS8996104 *Jun 25, 2009Mar 31, 2015Fe3 Medical, Inc.Patches and method for the transdermal delivery of a therapeutically effective amount of ironUS9044397Jul 9, 2013Jun 2, 2015Ethicon, Inc.Medical devices with galvanic particulatesUS9050452Dec 22, 2004Jun 9, 2015Johnson & Johnson Consumer Companies, Inc.Device for treatment of a barrier membraneUS9072884 *Sep 4, 2007Jul 7, 2015Axelgaard Manufacturing Company, Ltd.Differential diameter electrodeUS9101555Apr 9, 2015Aug 11, 2015Mary Kay Inc.Magnolia extract containing compositionsUS9272137May 11, 2011Mar 1, 2016Teva Pharmaceuticals International GmbhTransdermal methods and systems for the delivery of anti-migraine compoundsUS9295854Mar 12, 2013Mar 29, 2016Point Source, Inc.Light and bioelectric therapy padUS9394637Jul 16, 2013Jul 19, 2016Jacob Holm & Sons AgMethod for production of a hydroentangled airlaid web and products obtained therefromUS9402904Aug 29, 2014Aug 2, 2016Fe3 Medical, Inc.Method for transdermal iontophoretic delivery of chelated agentsUS9427578Feb 20, 2014Aug 30, 2016Teva Pharmaceuticals International GmbhPharmacokinetics of iontophoretic sumatriptan administrationUS9433772Dec 17, 2010Sep 6, 2016Teikoku Seiyaku Co., Ltd.Electrode device used in iontophoresis treatmentUS9592291Sep 26, 2014Mar 14, 2017Teva Pharmaceuticals International GmbhMethods for iontophoretically treating nausea and migraineUS20040267231 *Jun 30, 2003Dec 30, 2004Ying SunDevice for delivery of oxidizing agents to barrier membranesUS20050004550 *Jun 23, 2004Jan 6, 2005Ying SunMethods of treating a wound with galvanic generated electricityUS20050187580 *Feb 19, 2004Aug 25, 2005Skiba Jeffry B.Current producing surfaceUS20050192636 *Feb 18, 2005Sep 1, 2005Silverleaf Medical Products, Inc.Batteries and methods of manufacture and useUS20070083147 *Oct 2, 2006Apr 12, 2007Transcutaneous Technologies Inc.Iontophoresis apparatus and method to deliver antibiotics to biological interfacesUS20070088332 *Aug 22, 2006Apr 19, 2007Transcutaneous Technologies Inc.Iontophoresis deviceUS20070088341 *Aug 18, 2006Apr 19, 2007Skiba Jeffry BFootwear apparatus and methods of manufacture and useUS20070203534 *Jan 10, 2007Aug 30, 2007Robert TapperStimulating galvanic or slow AC current for therapeutic physiological effectsUS20080076345 *Mar 1, 2007Mar 27, 2008Aloys WobbenFire protectionUS20080114284 *Nov 9, 2007May 15, 2008Travanti Pharma Inc.Transdermal Systems for the Delivery of Ionic Agents Directly to Open Wounds and Surgically Repaired IncisionsUS20080122582 *Nov 29, 2006May 29, 2008Texas Instruments IncorporatedLocation Based Portable Device Feature DisablerUS20080146986 *Oct 18, 2007Jun 19, 2008Buckeye Pharmaceuticals, LlcChemical Compound Delivery Device And MethodUS20080234629 *Mar 21, 2008Sep 25, 2008John PetersenWater electrolysis to facilitate drug delivery by iontophoresisUS20080240479 *Oct 3, 2007Oct 2, 2008Sonic Innovations, Inc.Hydrophobic and oleophobic coating and method for preparing the sameUS20080287497 *Jul 28, 2008Nov 20, 2008Nupathe Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsUS20080287866 *Jan 31, 2008Nov 20, 2008Adam HellerMethods and compositions for the treatment of painUS20080288019 *Jan 31, 2008Nov 20, 2008Adam HellerElectrochemical management of painUS20080305154 *Jun 8, 2007Dec 11, 2008Activatek, Inc.Transdermal medicament patch and active electrode for sameUS20080319370 *Nov 3, 2006Dec 25, 2008Acrux Dds Pty Ltd.Method and System for Transdermal Drug DeliveryUS20090047572 *Aug 18, 2008Feb 19, 2009Micropower Electronics, Inc.Controlled pressure release for packaged batteries and associated systems and methodsUS20090062723 *Oct 13, 2008Mar 5, 2009Silverleaf Medical Products, Inc.Current producing surface for treating biologic tissueUS20090062897 *Sep 4, 2007Mar 5, 2009Jens AxelgaardDifferential diameter electrodeUS20090076479 *Nov 17, 2008Mar 19, 2009Ying SunDevice for treatment of barrier membranesUS20090099500 *Feb 28, 2007Apr 16, 2009Zvi NitzanMulti-function electrode and uses thereofUS20090254018 *Aug 24, 2006Oct 8, 2009Mizuo NakayamaElectrode assembly for freezing-type iontophoresis deviceUS20090299264 *Sep 28, 2006Dec 3, 2009Tti Ellebeau, Inc.Electrode Assembly for Dry Type IontophoresisUS20090317450 *Jun 19, 2008Dec 24, 2009Sebree Terri BPharmacokinetics of iontophoretic sumatriptan administrationUS20090318847 *Jun 19, 2008Dec 24, 2009Sebree Terri BPolyamine enhanced formulations for triptan compound iontophoresisUS20100057147 *Aug 27, 2008Mar 4, 2010Ali FassihTreatment of hyperhydrosisUS20100130910 *Jun 25, 2009May 27, 2010Berenson Ronald JPatches and method for the transdermal delivery of a therapeutically effective amount of ironUS20100130912 *Jun 25, 2009May 27, 2010Berenson Ronald JPatches and methods for the transdermal delivery of a therapeutically effective amount of ironUS20100137780 *Sep 25, 2009Jun 3, 2010Singh Rishi PApparatus and method for delivering a therapeutic agent to ocular tissueUS20100143515 *Feb 16, 2010Jun 10, 2010Mary Kay Inc.Magnolia extract containing compositionsUS20100249927 *Mar 25, 2010Sep 30, 2010Chunlin YangMedical devices with galvanic particulatesUS20100268335 *Apr 16, 2010Oct 21, 2010Chunlin YangMedical devices with galvanic particulatesUS20100272827 *Jul 7, 2009Oct 28, 2010Mir ImranMethod for transdermal iontophoretic delivery of chelated agentsUS20100286590 *May 7, 2010Nov 11, 2010Isis Biopolymer LlcIontophoretic device with improved counterelectrodeUS20110060419 *Sep 27, 2010Mar 10, 2011Jennifer Hagyoung Kang ChoiMedical devices with galvanic particulatesUS20110066100 *Aug 10, 2010Mar 17, 2011Sebree Terri BMethods for iontophoretically treating nausea and migraineUS20110087153 *Oct 12, 2010Apr 14, 2011Angelov Angel STransdermal Methods And Systems For The Delivery Of RizatriptanUS20110092881 *Oct 13, 2010Apr 21, 2011Isis Biopolymer Inc.Iontophoretic device with contact sensorUS20110112465 *Jan 20, 2011May 12, 2011Travanti Pharma Inc.Transdermal Systems for the Delivery of Ionic Agents Directly to Open Wounds and Surgically Repaired IncisionsUS20110159299 *Jul 16, 2010Jun 30, 2011Linforf Mattew RHydrophobic coating and methodUS20110160639 *Jul 2, 2008Jun 30, 2011Yanaki Jamal SCosmetic iontophoresis systemUS20110213294 *May 11, 2011Sep 1, 2011Nupathe, Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsUS20110213330 *May 11, 2011Sep 1, 2011Nupathe, Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsUS20110257612 *Apr 12, 2011Oct 20, 2011Kci Licensing, Inc.Reduced-pressure sources, systems, and methods employing a polymeric, porous, hydrophobic materialUS20120065575 *Mar 31, 2010Mar 15, 2012Simone Nadia LEONARDI KADERMethod and appliance for cosmetic skincareUS20150258035 *Feb 17, 2015Sep 17, 2015Fe3 Medical, Inc.Patches and Methods for the Transdermal Delivery of a Therapeutically Effective Amount of IronEP2123248A1May 21, 2009Nov 25, 2009Johnson and Johnson Consumer Companies, Inc.A composition comprising a PPAR-gamma agonist and method of treating facial skin defectEP2517754A1 *Dec 17, 2010Oct 31, 2012Teikoku Seiyaku Co., Ltd.Electrode device used for iontophoresis therapyEP2517754A4 *Dec 17, 2010Jul 3, 2013Teikoku Seiyaku KkElectrode device used for iontophoresis therapyWO2007035432A2 *Sep 14, 2006Mar 29, 2007Board Of Regents, The University Of Texas SystemReduction of the loss of zinc by its reaction with oxygen in galvanized steel and batteriesWO2007035432A3 *Sep 14, 2006Aug 2, 2007Univ TexasReduction of the loss of zinc by its reaction with oxygen in galvanized steel and batteriesWO2007120747A2 *Apr 12, 2007Oct 25, 2007Nupathe Inc.Transdermal methods and systems for the delivery of anti-migraine compoundsWO2007120747A3 *Apr 12, 2007Apr 24, 2008Travanti Pharma IncTransdermal methods and systems for the delivery of anti-migraine compoundsWO2008094663A3 *Jan 31, 2008Oct 9, 2008Adam HellerElectrochemical management of painWO2010002363A1 *Jul 2, 2008Jan 7, 2010Activatek, Inc.Cosmetic iontophoresis systemWO2010111502A2Mar 25, 2010Sep 30, 2010Ethicon, Inc.Medical devices with galvanic particulatesWO2011130112A1Apr 8, 2011Oct 20, 2011Ethicon, Inc.Medical devices with galvanic particulatesWO2012044538A1Sep 23, 2011Apr 5, 2012Advanced Technologies And Regenerative Medicine, LlcMedical devices with galvanic particulatesWO2013190489A1 *Jun 19, 2013Dec 27, 2013Cetroni Bruno MassimoDevice for transdermal and/or intradermal transport* Cited by examinerClassifications U.S. Classification604/501, 604/20International ClassificationA61N1/32, A61N1/30, A61N1/20Cooperative ClassificationA61N1/0428, A61N1/0492, A61K8/20, A61N1/0436, A61N1/205, A61K2800/28, A61K8/27, A61K2800/83, A61K8/365, A61N1/325, A61Q19/08, A61K8/368, A61Q19/02, A61N1/044, A61Q19/008, A61N1/303, A61N1/0448, A61K8/19, A61Q19/10, A61N1/30European ClassificationA61Q19/08, A61K8/20, A61K8/365, A61Q19/10, A61K8/27, A61K8/368, A61Q19/00S, A61Q19/02, A61K8/19, A61N1/04E1I1S, A61N1/04E1I, A61N1/04E2P, A61N1/30B, A61N1/04E1I1M, A61N1/30Legal EventsDateCodeEventDescriptionMar 21, 2005ASAssignmentOwner name: JOHNSON & JOHNSON CONSUMER COMPANIES, INC., NEW JEFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUN, YING;LIU, JUE-CHEN;WU, JEFFREY M.;AND OTHERS;REEL/FRAME:016379/0743;SIGNING DATES FROM 20050304 TO 20050310Owner name: JOHNSON & JOHNSON CONSUMER COMPANIES, INC., NEW JEFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SUN, YING;LIU, JUE-CHEN;WU, JEFFREY M.;AND OTHERS;SIGNING DATES FROM 20050304 TO 20050310;REEL/FRAME:016379/0743Jul 1, 2015ASAssignmentOwner name: JOHNSON & JOHNSON CONSUMER INC, NEW JERSEYFree format text: MERGER AND CHANGE OF NAME;ASSIGNORS:JOHNSON & JOHNSON CONSUMER COMPANIES, LLC;JOHNSON & JOHNSON CONSUMER INC.;REEL/FRAME:036041/0605Effective date: 20150623Owner name: JOHNSON & JOHNSON CONSUMER COMPANIES, LLC, DELAWARFree format text: MERGER;ASSIGNOR:JOHNSON & JOHNSON CONSUMER COMPANIES, INC.;REEL/FRAME:036043/0978Effective date: 20150623Jul 21, 2015ASAssignmentOwner name: JOHNSON & JOHNSON CONSUMER INC., NEW JERSEYFree format text: CORRECTIVE ASSIGNMENT TO CORRECT THE MERGED ENTITY NEW NAME PREVIOUSLY RECORDED AT REEL: 036041 FRAME: 0605. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER & CHANGE OF NAME;ASSIGNOR:JOHNSON & JOHNSON CONSUMER COMPANIES, LLC;REEL/FRAME:036143/0449Effective date: 20150623RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services